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With transplant rejection rendered a minor concern and survival rates after liver 
transplantation (LT) steadily improving, long-term complications are attracting more 
attention. Current immunosuppressive therapies, together with other factors, are 
accompanied by considerable long-term toxicity, which clinically manifests as renal 
dysfunction, high risk for cardiovascular disease, and cancer. 
This thesis investigates the incidence, causes, and risk factors for such renal 
dysfunction, cardiovascular risk, and cancer after LT. Long-term effects of LT are 
further addressed by surveying the quality of life and employment status of LT 
recipients. 
The consecutive patients included had undergone LT at Helsinki University Hospital 
from 1982 onwards. Data regarding renal function – creatinine and estimated 
glomerular filtration rate (GFR) – were recorded before and repeatedly after LT in 
396 patients. The presence of hypertension, dyslipidemia, diabetes, impaired fasting 
glucose, and overweight/obesity before and 5 years after LT was determined among 
77 patients transplanted for acute liver failure.  
The entire cohort of LT patients (540 patients), including both children and adults, 
was linked with the Finnish Cancer Registry, and numbers of cancers observed were 
compared to site-specific expected numbers based on national cancer incidence rates 
stratified by age, gender, and calendar time.  
Health-related quality of life (HRQoL), measured by the 15D instrument, and 
employment status were surveyed among all adult patients alive in 2007 (401 
patients). The response rate was 89%. Posttransplant cardiovascular risk factor 
prevalence and HRQoL were compared with that in the age- and gender-matched 
Finnish general population. 
The cumulative risk for chronic kidney disease increased from 10% at 5 years to 16% 
at 10 years following LT. GFR up to 10 years after LT could be predicted by the GFR 
at 1 year. In patients transplanted for chronic liver disease, a moderate correlation of 
pretransplant GFR with later GFR was also evident, whereas in acute liver failure 
patients after LT, even severe pretransplant renal dysfunction often recovered. By 5 
years after LT, 71% of acute liver failure patients were receiving antihypertensive 
medications, 61% were exhibiting dyslipidemia, 10% were diabetic, 32% were 
overweight, and 13% obese. Compared with the general population, only 
hypertension displayed a significantly elevated prevalence among patients – 2.7-fold 
– whereas patients exhibited 30% less dyslipidemia and 71% less impaired fasting 
glucose.  
The cumulative incidence of cancer was 5% at 5 years and 13% at 10. Compared with 
the general population, patients were subject to a 2.6-fold cancer risk, with non-
melanoma skin cancer (standardized incidence ratio, SIR, 38.5) and non-Hodgkin 
lymphoma (SIR 13.9) being the predominant malignancies. Non-Hodgkin lymphoma 
was associated with male gender, young age, and the immediate posttransplant 
period, whereas old age and antibody induction therapy raised skin-cancer risk. 
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HRQoL deviated clinically unimportantly from the values in the general population, 
but significant deficits among patients were evident in some physical domains. 
HRQoL did not seem to decrease with longer follow-up. Although 87% of patients 
reported improved working capacity, data on return to working life showed marked 
age-dependency: Among patients aged less than 40 at LT, 70 to 80% returned to 
work, among those aged 40 to 50, 55%, and among those above 50, 15% to 28%. The 
most common cause for unemployment was early retirement before LT. Those 
patients employed exhibited better HRQoL than those unemployed. 
In conclusion, although renal impairment, hypertension, and cancer are evidently 
common after LT and increase with time, patients’ quality of life remains comparable 
with that of the general population.  
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Abbreviations 
ALF, acute liver failure 
ALG, antilymphocyte globulin 
ATG, antithymocyte globulin 
BMI, body mass index 
CI, confidence interval 
CKD, chronic kidney disease 
CLD, chronic liver disease 
CMV, cytomegalovirus 
CNI, calcineurin inhibitor 
CV, cardiovascular 
EBV, Epstein Barr virus 
EC-MPS, enteric-coated mycophenolate sodium  
ESRD, end-stage renal disease 
GFR, glomerular filtration rate 
HbA1c, glycated hemoglobin 
HCC, hepatocellular carcinoma 
HCV, hepatitis C virus 
HDL, high-density lipoprotein 
HRQoL, health-related quality of life 
IFG, impaired fasting glucose 
IL-2, interleukin-2 
INR, international normalized ratio 
LDL, low-density lipoprotein 
LT, liver transplantation 
MELD, Model for End-Stage Liver Disease 
MMF, mycophenolate mofetil 
MTOR, mammalian target of rapamycin 
PBC, primary biliary cirrhosis 
PSC, primary sclerosing cholangitis 
PTLD, posttransplant lymphoproliferative disorder 
SIR, standardized incidence ratio 
SPR, standardized prevalence ratio  
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Introduction 
Thomas Starzl and colleagues, working in Denver, Colorado, attempted the first 
human liver transplantation (LT) in 1963, but had to wait until 1967 for their first 
clinically successful LT.1,2 Their success was a year later reinforced by the initiation 
of the first European clinical liver transplant program in Cambridge, UK, led by Roy 
Calne.1,3-5 With an immunosuppression largely based on steroids and azathioprine, 
however, many patients were subject to fatal graft rejection; following transplantation 
less than 30% survived more than one year.1  
In the early 1980s, the discovery of the potent immunosuppressant cyclosporine 
revolutionized the field by rendering graft loss due to rejection infrequent.1 This 
success consequently enabled LTs to begin a transformation from a rather 
experimental procedure to a definitive therapy for end-stage liver disease. Shortly 
hereafter, with knowledge acquired by the Finnish surgeon Krister Höckerstedt at 
Calne’s center in Cambridge, and through a joint team effort, the Finnish liver 
transplant program commenced. In 1982, the first Nordic LT was carried out in 
Helsinki.6 
Since then, numerous advances in surgical technique, organ preservation, 
perioperative anesthesia, postoperative care, and clinical immunosuppression, as well 
as improved recipient selection and donor management have together gradually 
defeated the initial enemies of long-term survival – as evidenced by a current 10-year 
survival rate of roughly 60%, and at some centers of above 70%.1,7-10 Concurrently, 
annual numbers of LTs performed in Europe alone have steadily increased from 25 in 
1980 to 5531 in 2007.8 By 2008, more than 80 000 LTs had been performed in 
Europe.8 In Finland, the figure has stabilized at around 50 LTs annually.7  
With fatal rejection made rare, the transplant community is now increasingly 
confronted by a new challenge: long-term complications.11,12 Such complications – 
including especially renal dysfunction, malignancies, and cardiovascular disease – 
frequently contribute to late mortality.8,12-17 Whereas toxicity from the life-long use of 
cyclosporine and the more recent agent tacrolimus, together with side-effects from 
concomitant immunosuppressants, are primarily implicated in the pathogenesis of 
these long-term complications, other potential causative factors are recognized as 
well.12,16,18-20 The relative significance of each factor, however, remains vague, and 
the full extent of the problem in the setting of LT has, thus far, been scantily 
addressed. Vast research in the field has, moreover, yielded numerous new 
immunosuppressive agents, such as mycophenolate, sirolimus, and everolimus, 
which, through their distinct side-effect profiles, now offer transplant physicians the 










The regular occurrence of long-term complications has naturally inspired 
enormous interest in developing strategies to prevent such complications, identifying 
the optimal degree of immunosuppression, recognizing regimens with less adverse 
effects, characterizing means to tailor immunosuppression, implementing appropriate 
follow-up screenings, and uncovering proper forms of therapy for complications once 
they occur. Essential for such achievements is, on the other hand, that the incidences, 
causes, and risk factors for the late complications first be accurately recognized. Until 
recent years, large-scale efforts to obtain such data have been restricted by rather 
small numbers of long-term survivors.  
In Finland, data on the occurrence of long-term complications has been lacking. 
Results from different centers may, furthermore, differ, likely because of differing 
patient characteristics and immunosuppression regimens. Moreover, because crude 
survival times now show an impressive rise, the quality of life of long-term survivors 
– likely impacted by complications – is emerging as an important outcome measure.21 
To date, quality-of-life issues have, however, been poorly explored.22 
 This thesis addresses the issue of long-term nonhepatic complications following 
LT by exploring the incidence of renal dysfunction, malignancies, and cardiovascular 
risk. The influence of time after LT and the impact of transplantation-related factors 
such as immunosuppression on the appearance of these complications also deserved 
investigation. Finally, overall outcome is evaluated by means of posttransplant 
quality of life and working capacity assessment. These findings may aid in 
developing means to use the currently available tools to maximize favorable outcome. 
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Review of the literature 
LIVER TRANSPLANTATION ACTIVITY 
Indications  
Change over time in indications. Recent years reveal a changing pattern of liver 
transplant indications. According to international liver registries, various liver tumors 
– in the early days constituting up to 50% of all indications – have gradually given 
way to cirrhosis, which, nowadays accounts for the majority of LTs performed in 











Viral + alcoholic 4% 0%
Primary biliary cirrhosis 11% 41%
Unknown causes 8% 16%
Autoimmune 4% 6%
Other 2% 6%
Liver tumor 14% 8%
Hepatocellular carcinoma 84% 65%
Cholangiocellular carcinoma 3% 2%
Other 13% 33%
Cholestatic disease 10% 22%
Primary sclerosing cholangitis 43% 69%
Biliary atresia 41% 26%
Other biliary diseases 16% 6%
Acute liver failure 9% 21%
Metabolic and other diseases 9% 9%
Nonbolded percentages are proportions of the respective main groups.
Data from references 8 and 23.




Whereas primary biliary cirrhosis (PBC) had been the main underlying condition, 
alcoholic cirrhosis and viral hepatitis (mostly hepatitis C, HCV) have now become 
the two most common forms of cirrhosis leading to LT, representing 33% and 38% of 
LTs performed for cirrhosis in Europe.8 In Finland, however, alcoholic cirrhosis and 
viral hepatitis account for only 10% and 3% of all LTs, with the predominant chronic 
conditions being PBC and primary sclerosing cholangitis (PSC).23 These account for 
15% and 16% of all LTs performed in Finland, where PSC has in recent years 
surpassed PBC as the single most common indication. Acute liver failure (ALF) is a 
more common indication for LT in Finland (21% of all LTs) than in Europe (9%) or 
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in the USA (6-9%).8,9 Liver tumors, representing 14% of LTs performed in Europe 8 
and 8% in Finland,23 currently consist mainly of hepatocellular carcinoma (HCC); 
other tumor types are rarely considered suitable for LT.1 In children, the leading 
indication for transplantation is cholestatic liver disease.8,9 
Timing of LT in current indications. In general, any patient with a liver disease 
resulting in life-threatening complications and a prognosis of one year of life or less, 
or with the inability to sustain a normal quality of life should be considered for 
LT.1,24,25 The modern approach is to pursue optimal timing of LT: when the patient 
will derive maximum survival benefit from transplantation.24,26,27 In practice, chronic 
liver disease (CLD) patients are usually considered for LT when they begin to show 
signs of hepatic decompensation (refractory ascites, hepatic encephalopathy, recurrent 
variceal hemorrhage, jaundice, coagulopathy, hypoalbuminemia, recurrent infections, 
or hepatorenal syndrome), or when they exhibit unbearable or disabling symptoms 
such as intractable pruritus.25,27,28  
In PSC, LT is also considered in the case of recurrent cholangitis, rapid disease 
progression (as indicated by symptoms, biochemical markers, or cholangiographic 
findings), or a strong suspicion of progression to hepatobiliary malignancy (as 
indicated by tumor markers, radiology, or significant dysplasia in repeated biliary 
brush cytology).29,30  
In the case of alcoholic cirrhosis, concern for relapsing alcohol abuse after LT 
has produced a widely adopted prerequisite of a 6-month abstinence period before 
consideration for LT.1,11,17,31,32 The underlying rationale is to identify candidates with 
higher risk for recidivism, to allow time for adequate therapy for addiction, but also 
to identify cases where liver function may recover to a level that makes LT 
unnecessary.1,11,17,31,32 The 6-month rule is, however, criticized as being based on no 
solid evidence, and hence, many experts recommend replacing such fixed periods 
with a more careful evaluation of each patient by addiction specialists.1,17,31,32  
In asymptomatic cirrhosis and viral hepatitis, an additional motive for LT is 
concomitant HCC.1 According to the widely adopted Milan criteria,33 LT is a 
therapeutic option for HCC when one solitary HCC lesion ≤ 5 cm is evident or one to 
three HCC lesions, with none exceeding 3 cm. 
Although the Kings College criteria 34 and Clichy criteria 35 are widely used, no 
universally standardized criteria dictate when ALF requires LT.1,36 In Finland, the 
Kings College criteria are chiefly employed in the decision to proceed to LT.  
Pretransplant evaluation. Liver transplant candidates undergo thorough 
evaluation in a multidisciplinary setting, including not only accurate assessment of 
liver pathology and severity of liver disease, but also evaluation of cardiopulmonary 
and renal function, screening for significant infections, possible infection foci, and 
co-morbidities, as well as comprehensive psychosocial evaluation.1,17 
 
Contra-indications 
Because of the universal shortage of organs for transplantation, LTs are performed 
only in patients for whom a reasonable prognosis is predicted.1,25 Medical advances, 
however, continuously reduce the list of contra-indications. Currently, absolute 
contra-indications include recent or active malignancy – with exceptions such as 
HCC and basal cell carcinoma – uncontrolled infection, active alcohol- or drug abuse, 
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inability to comply with a complex posttransplant medical regimen and follow-up, 
and physical illnesses curtailing life expectancy such as advanced cardiopulmonary 
disease or major irreversible cerebral injury.1,17,27,37 
The many conditions recognized as relative contra-indications differ among 
transplant centers.1,11,17,27,38 As some are manageable, they often are regarded more as 
risk factors for adverse outcome and are always weighed on a case-by-case basis.27 
 
Organ donors 
In Western countries, the clear majority of LTs involve liver grafts from brain-dead 
donors.11 This is, furthermore, the only form of LT practiced in Finland.7 Most 
allocation policies also involve this type of LT.27 The continuing organ shortage has, 
however, motivated efforts to increase the organ pool by awareness programs to 
increase donation rates, by expanding medical criteria for acceptable organs 
(extended-criteria donors), by employing organ donation after cardiac death (non-
heart-beating donors), by splitting a liver for two recipients, and by accepting living 
partial-liver donors.1,11,38,39  
Although this choice currently makes up a mere 3% to 4% of LTs in the USA 
and Europe, many Asian countries are, for cultural reasons, using living donors 
almost exclusively.11,39  
An ideal brain-dead donor is aged less than 50 to 60, presenting with normal 
liver and kidney values and stabilized hemodynamics, is devoid of hepatobiliary 
disease, severe abdominal trauma, systemic infection, or malignancy.37 Use of 
extended-criteria donors – including older donors, steatosed grafts, prolonged 
intensive care, elevated serum sodium, positive viral serology, and history of 
malignancy – is, together with use of non-heart-beating donors, associated with more 
postoperative complications and increased mortality.11,37-39 
 
Organ allocation 
The scarcity of donated organs relative to patients’ need for them forces society to 
generate allocation policies, prioritizing scarce organs for those needing them most 
urgently. In most transplant programs, an available donor liver is, among compatible 
candidates, prioritized to the patient exhibiting the highest degree of medical 
urgency.27,37 In LT, compatibility refers to ABO blood group compatibility as well as 
donor and recipient size and age similarity.24,40,41 The role of other histocompatibility 
factors is negligible.42 Although ALF and high-urgency retransplantation-
necessitating conditions are universally given the highest priority, criteria of medical 
urgency for CLD differ.27,37  
The US Model. The United States has, since 2002, allocated liver grafts 
according to candidate risk scores derived from the Model for End-Stage Liver 
Disease (MELD), a scoring system based on INR, creatinine, and bilirubin; MELD 
predicts waiting-list mortality and thus parallels disease severity.9,43-45 Some 
conditions may merit additional points,27 and a modification of this model serves for 
pediatric patients.9,45 
European models. In Europe, allocation policies of the six main organ exchange 
organizations differ, with some inter-organizational collaboration regarding surplus 
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organs. While Spain, France, Italy, and the UK administer their own national 
organizations, Austria, Belgium, Croatia, Germany, Luxemburg, the Netherlands, and 
Slovenia collaborate in the agency Eurotransplant.1,27 The Nordic countries, including 
Finland, cooperate in Scandiatransplant.7 In 2006, Eurotransplant adopted a MELD-
based allocation system similar to that in the USA.27 The UK has recently developed 
and implemented a different scoring system: the United Kingdom Model for End-
stage Liver Disease (UKELD), with its algorithm adding sodium level to the factors 
included in MELD.25,27 
Scandinavian model. Within Scandiatransplant, high-urgency candidates are 
entitled to the first available liver graft from any member country within 3 days, 
whereas, in elective cases, donor organs are offered to collaborating centers only if 
not needed locally.1,7  
Finnish model. Finland has avoided competition for organs between centers by 
having all LTs centralized in Helsinki. This, together with overall relatively small-
scale LT activity and a short waiting-list, enables the allocation of donor livers based 
on careful clinical judgement – comprehensively balancing donor and recipient risks 
individually – instead of allocation based on rigorous mathematical algorithms. 
 
Surgical procedures 
Conventional technique. As detailed reviews of surgical techniques involved in LT 
operations and principles of graft preservation and perioperative anesthesia are 
available elsewhere,1,37,41 only some basic aspects need be discussed here. Following 
the exposure and dissection of relevant structures, ligation and cutting of the bile 
duct, crossclamping and cutting of the hepatic artery, portal vein, and infra- and 
suprahepatic caval vein, as well as removal of the diseased liver, the donor liver is 
usually placed in the same location (orthotopically).41 Implantation of the liver in 
another location (heterotopically) is linked to inferior outcome and during the last two 
decades has been performed in less than 2/1000 recipients in Europe.8,41  
Anhepatic phase. Clamping of both the inferior caval vein and the portal vein 
poses a hemodynamic challenge which can be overcome either by an extracorporeal, 
pump-driven veno-venous bypass or by caval-vein-sparing surgery (Piggyback).1,37,41 
Both techniques offer some potential complications such as thrombosis.41 At Helsinki 
University Central Hospital, the veno-venous bypass is not in use, and a modified 
Piggyback method is practiced mainly in patients with compromised cardiac function. 
Reconstructive techniques. The subsequent reconstruction of the vasculature and 
bile ducts are often by end-to-end anastomoses, but variations exist.1,37,41 In Helsinki, 
end-to-end biliary anastomosis is without a T-tube, whereas PSC patients undergo 
reconstruction of the biliary tract by anastomosis of the donor bile duct to a small 
bowel loop (Roux-en Y).37,41 Overall, several technical modifications of and 
variations in the transplantation procedure exist. Which of these are applied depends 
on characteristics of the recipient and the routine practice of the center, as well as the 
preference of the surgeon.41 
Alternative surgical approaches. Size-reduction of a graft permits adult-donor 
livers to be used in children. An alternative, efficiently preserving the limited organ 
supply, is splitting a liver graft for two recipients – a method constituting 
approximately 3% to 5% of LTs performed in the USA and Europe.8,9 Domino LT, 
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another innovative strategy, refers to a rather unusual situation where a patient with a 
particular disease, most frequently familial amyloid polyneuropathy, undergoes 
conventional LT, but simultaneously donates his or her native liver to some other 
patient awaiting LT.46,47  
An evolving approach in ALF is to resect the patient’s liver and transplant a 
partial graft adjacent to the resected diseased liver (auxiliary LT).1 The advantage of 
such a procedure is the potential option to discontinue immunosuppression if the 
native liver, despite its poor prognosis, recovers. To date in Europe, auxiliary LT has 
been performed in less than 2% of all urgent LTs.8 Despite the alternative surgical 
innovations, in Europe, LTs still performed with full-sized liver grafts from brain-
dead donors amount to more than 80%.8 
 
As evident in this overview, variations presently exist between nations and centers in 
their LT activity. Such variations, in addition to the effect of immunosuppression to 
be discussed, may influence the outcome following LT, the occurrence of 




The immune response in liver transplantation 
Following LT, the recipient’s immune system recognizes the implanted liver as 
foreign and consequently launches an immune response resulting in graft rejection. 
The underlying mechanisms by which such an immune response is mediated are 
complex, and despite intense research, remain incompletely understood.1,48-51 
According to current understanding, cellular reactions, mainly mediated by T-
lymphocytes, play the predominant role, with the role of antibody-mediated responses 
apparently trivial.1,48-51 As more thoroughly outlined in Figure 1, the rejection 
response can be divided into four phases: antigen recognition, lymphocyte activation, 
lymphocyte proliferation, and graft inflammation.1  
Antigen recognition in recipient lymphoid tissue occurs either when recipient T 
lymphocytes recognize donor major-histocompatibility-complex-molecules expressed 
on donor-derived antigen-presenting cells (direct pathway), or when recipient T 
lymphocytes recognize donor-derived antigens in the context of self-major 
histocompatibility-complex-molecules expressed on recipient antigen-presenting cells 
(indirect pathway).1,48,50 Some propose that, with a massive migration of graft-derived 
donor hematolymphoid cells (such as antigen-presenting cells) into recipient 
lymphoid tissue, the direct pathway predominates as a cause for acute rejection early 
posttransplant, whereas indirect pathways may predominate later on when donor 
antigen-presenting cells have slowly died out.48,50 This phenomenon helps explain 
why rejection risk gradually decreases with time.48,50 Moreover, the large component 
of liver graft-derived immunocompetent-mature donor T lymphocytes, together with 
a weakened recipient immune system, permits the highly unusual event of graft-



















   


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Principles of immunotherapy 
To prevent graft rejection following LT, life-long immunosuppression therapy is, in 
the vast majority of patients, necessary.11,14,53-55 In practice, successful posttransplant 
care relies on a continuous balance in immunosuppressive therapy between too mild – 
leading to rejection, and too intense – resulting in toxicity. Adding to the challenge is 
the variation in optimal degree of immunosuppression from patient to patient. This 
degree generally decreases with time; along with rejection risk.54 Although some 
anecdotal cases of complete tolerance have been reported, no means to identify such 
cases yet exist.56  
Standard regimens usually consist of a combination of three types of agents: a 
calcineurin inhibitor (CNI) – the mainstay of immunosuppressive therapy – is 
typically combined with antimetabolites and corticosteroids.1,11,37,53,54 The advantage 
of such diversified therapy is that it increases efficacy while simultaneously allowing 
lower doses of each drug and, hence, minimizing drug-specific toxicity.14,54 The most 
common drugs currently in clinical use, the era of their clinical introduction, and their 
side-effect profiles are summarized in Table 2.14,57-71  
 
Calcineurin inhibitors 
CNIs, comprising cyclosporine and tacrolimus, are thought to achieve their 
immunosuppressive effect primarily by inhibiting the activation of T lymphocytes 
(Figure 1).48,51,72 Cyclosporine binds to the cytosolic protein cyclophilin, whereas 
tacrolimus, a macrolid compound exhibiting 100-fold greater potency than 
cyclosporine, binds to a corresponding protein called the FK506-binding protein 
12.1,48,51,54,72 These protein-drug complexes competitively block signal transduction 
through the calcineurin pathway, which in turn results in inhibition of the 
transcription of several genes, including genes for interleukin-2 (IL-2), critical for the 
activation of T lymphocytes (Figure 1).1,48,51,54,72 CNIs selectively suppress 
lymphocyte reactions, while other cell lines are not significantly inhibited.1  
Both CNIs are primarily metabolized in the liver via the cytochrome P450 3A4 
system, which renders them able to function in multiple clinically important drug 
interactions.14,55 Accordingly, as small differences in blood concentration can cause 
therapeutic failure or adverse effects, drug levels require regular monitoring.14 
Following an initial weight-based dosage twice daily, subsequent dosage is 
guided by trough levels as well as by signs of adverse effects. Target levels vary 
between centers and depend also on concomitant medications.1 Presently a newer 
microemulsified formulation of cyclosporine is available which is less dependent on 
biliary flow for absorption and exhibits more consistent bioavailability.1 More 
recently, a prolonged-release formulation of tacrolimus has also been developed, 
allowing once-daily dosing. 
Several adverse effects common to both CNIs are recognized, most notably 
nephrotoxicity and neurotoxicity, but with noteworthy differences, such as that 
tacrolimus is more diabetogenic, and cyclosporine causes more dyslipidemia and 




Cyclosporine Tacrolimus Corticosteroids Azathioprine Mycophenolate
mTOR 
inhibitors a
Era of clinical 
introduction 1980s 1990s 1960s 1960s 1990s 2000s
Adverse effect
Alopecia - + - - + -
Bone marrow 
suppression + + - +++ ++ +
Skin / mucosal lesions
-
+ (rash, 




Gastrointestinal toxicity + ++ ++ + +++ b +
Hepatotoxicity + + - ++ - +
Hirsutism / gingival 
hyperplasia + - - - - -
Hyperglycemia / 
diabetes + ++ +++ - - + (?)
Hyperlipidemia ++ + ++ - - +++
Hypertension +++ ++ +++ - - +
Impaired wound 
healing - - + - - ++
Myalgia / arthralgia - - - - + ++
Nephrotoxicity +++ +++ - - - + (proteinuria)
Neurotoxicity ++ c ++ c + (psychiatric) - + (cephalalgia) -
Osteoporosis + + +++ - - -
Peripheral edema - - ++ - - ++
Pneumonitis - - - - - +
Each drug also possesses specific side-effects in addition to those listed in the table.
-, not reported; +, rarely reported; ++, commonly reported; +++, very frequently reported; ?, data scarce or discordant
a The side-effect profile of everolimus may differ from that of sirolimus (limited data available)
b Enteric-coated mycophenolate sodium may have fewer gastrointestinal side-effects than mycophenolate mofetil
Abbreviation: mTOR, mammalian target of rapamycin (sirolimus and everolimus)
Sources are references 14, 57-71.
Table 2. Compilation of the most frequent side-effects of immunosuppressive drugs, as used in the 
setting of liver transplantation.
c Peripheral neuropathy, cephalalgia, tremor, convulsions; Tacrolimus reported to be somewhat more neurotoxic than 




 CNI nephrotoxicity. Acute CNI nephrotoxicity is characterized by acute, dose-
related, reversible afferent arteriolar vasoconstriction and hence a decrease in kidney 
function.73,74 This effect is exaggerated by intravenous administration, and usually 
resolves within 1 to 2 days of dose reduction.73 Acute CNI nephrotoxicity is also 
suggested to include acute tubular dysfunction, and vasoconstriction-associated 
ischemia may also injure the endothelium, hence contributing to thrombotic 
microangiopathy in the glomeruli.73,74 Possible prothrombotic properties of CNI may 
further enhance such processes.74 In contrast, chronic CNI nephrotoxicity involves 
several complex and partly undefined mechanisms which lead to the development of 
chronic irreversible functional impairment with associated morphological and 
histological changes to all compartments of the kidneys.1,74 In contrast to the acute 
form, the development of chronic CNI nephrotoxicity, which often develops 
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gradually over some years, seems not to be directly related to the degree of systemic 




Corticosteroids have, since the start of their use, been a critical component of 
posttransplant immunotherapy.1 Their mechanisms of action are diverse, as they 
interact with intracellular receptors expressed in almost every cell of the body, 
subsequently regulating gene transcription.48,51,54,72 This explains the substantial list 
of frequently observed, well-documented side-effects: insulin resistance, weight gain, 
sodium and fluid retention, hypertension, hyperlipidemia, osteoporosis, aseptic bone 
necrosis, myopathy, cataracts, glaucoma, cushingoid appearance, peptic ulcer, 
cosmetic changes (acne, hirsutism, skin fragility), susceptibility to infections, 
impaired wound healing, neuropsychiatric symptoms (depression, mania, psychosis, 
insomnia), amenorrhea in women, and growth retardation in children (Table 
2).1,48,51,54,72 
Corticosteroids also express a broad spectrum of immunosuppressive properties. 
Primarily, the steroid-receptor complex targets particular transcription factors, 
reducing the synthesis of multiple immunomodulating cytokines essential for T 
lymphocyte activation (Figure 1).1,48,72 Other properties of key significance in the 
setting of LT include suppressing antibody and complement binding, inhibiting 
macrophage responses to alloantigens, suppressing eicosanoid production, and down-
regulating adhesion molecules, as well as causing increased expression of 
transforming growth factor-β.1,48,51,54,72  
 
Antimetabolites 
Antimetabolites, including azathioprine and mycophenolate (mycophenolate mofetil, 
MMF, and enteric-coated mycophenolate sodium, EC-MPS), interfere with purine 
nucleotide synthesis and metabolism, thereby blocking the differentiation and 
proliferation of lymphocytes (Figure 1).1,48,54,72 Azathioprine, an imidazole derivative 
of mercaptopurine that is rapidly metabolized to 6-mercaptopurine, acts as a purine 
analogue antagonizing purine synthesis unselectively with consequences for various 
cell types, although those cell types dividing rapidly, such as lymphocytes, are most 
susceptible.1 In contrast, mycophenolate, a 2-morpholinoethyl ester of mycophenolic 
acid, has a relatively selective effect on lymphocytes.1,72 Specifically, MMF and MPS 
inhibit inosine monophosphate dehydrogenase II, leading to suppression of the de 
novo purine synthesis pathway, which, unlike in other cell types, is a vital pathway 
for lymphocyte proliferation.1,51,72  
The most common side-effects of antimetabolites are dose-dependent bone 
marrow suppression and gastrointestinal symptoms (Table 2).1,51,72 Dosage is weight-
based and adjusted by effect and signs of toxicity.1 The EC-MPS preparation was 
originally developed with the aim of reducing gastrointestinal side-effects from 




Mammalian target of rapamycin inhibitors 
Sirolimus (rapamycin), a macrolid compound structurally similar to tacrolimus, also 
mediates its action by binding to the FK506-binding protein 12.48,51,72 The sirolimus-
protein complex does not, however, inhibit the calcineurin pathway. Instead, it is 
suggested that this complex inhibits the mammalian target of rapamycin (mTOR) 
pathway, thereby blocking signals from a variety of cell surface receptors (including 
IL-2), with resultant suppression of cytokine-driven T lymphocyte proliferation 
(Figure 1).48,51,72 Other mechanisms of action have also been described.48 Recently 
this drug class has also included everolimus, a compound derived from sirolimus and 
differing structurally by only one molecule. Dosage of both compounds is targeted 
based on blood levels. Metabolism occurs through the cytochrome P450 3A4 system, 
with concomitant potential drug interactions. Primary side-effects include 
dyslipidemia, cytopenias, rash, oral ulcerations, arthralgia, diarrhea, and occasionally 
pneumonitis (Table 2).1,51  
Concern regarding impaired wound healing and suspicion of a higher rate of 
hepatic artery thrombosis in early randomized trials have thus far limited the use of 
mTOR inhibitors in LT.51,54 More recently, even mTOR inhibitor-induced proteinuria 
has been described in renal transplant patients.76-78 Nevertheless, supported by results 
from experimental studies suggesting that mTOR inhibitors may promote graft 
tolerance and may exhibit antitumor activity, a number of potential roles for mTOR 
inhibitors in LT are projected, and intense research is underway.54,79 
 
Antibody therapies 
Intravenously administered antibodies target either specific T lymphocyte cell-surface 
antigens (monoclonal antibodies) or multiple cell-surface molecules (polyclonal 
antibodies), subsequently exerting their effects through lymphocyte depletion, 
modulation of lymphocyte function, or a combination of both (Table 3).1,48,51,54,72,80 
Following initial doses, flu-like symptoms may occur, ones related to intravascular 
release of cytokines by collapsing lymphocytes (cytokine-release syndrome), 
especially during treatment with animal-derived antibodies (antithymocyte globulin, 
ATG, antilymphocyte globuli, ALG, and OKT3).1,51 The symptoms, including fever, 
headache, diarrhea, nausea, bronchospasm, and fluctuations of blood pressure, can be 







Adverse effects of immunosuppression  
In addition to these drug-specific side-effects, immunosuppression itself is, regardless 
of regimen, associated with increased risk for two adverse effects: infection and 
malignancy.81 
Immunosuppression and infections. Suppression of the immune system, the main 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































increased susceptibility to infections. Because therapies mainly suppress T 
lymphocyte function, this increased susceptibility involves pathogens whose 
eradication under normal circumstances fundamentally necessitates T lymphocyte 
responses.81,82 Such pathogens include cytomegalovirus (CMV) and the Epstein Barr 
(EBV), varicella zoster, and herpes simplex viruses, Pneumocystis jiroveci (formerly 
carinii), and aspergillus, as well as other opportunistic microbes.81,82 The degree of 
overall infection risk is determined by the dosage, duration, and chronological 
sequence of immunosuppressive therapy.1,82 In addition to promoting susceptibility to 
various opportunistic pathogens, immunosuppression typically also enables common 
non-opportunistic pathogens to cause more aggressive infections, and often reduces 
signs and symptoms of infection.1,82 In clinical reality, however, not only does 
pharmacological immunosuppression predispose transplanted patients to infections, 
but so also does impairment in pre-transplant health, complex surgical procedures, 
disrupted integrity of mucocutaneous barriers (catheters, intubation, drains), 
hospitalization, possible graft-transmitted pathogens, infection with 
immunomodulatory viruses, and latent infection in the recipient.1,82 In the long-term, 
corticosteroids, for instance, predispose to microbe invasion by causing 
mucocutaneous fragility and impairing wound healing.1,82  
Oncogenic effects of immunosuppression. The link between immunosuppression 
and increased cancer occurrence was, through epidemiological awareness, recognized 
decades ago.83,84 In general, the risk for malignancy seems closely to correlate with 
cumulative exposure to immunosuppression.85 Underlying oncogenic mechanisms 
remain incompletely elucidated, but the literature provides several hypotheses. First, 
chronic immunosuppression depresses certain components of the host immune system 
such as the natural killer cells involved in antitumor surveillance and in early 
destruction of arising neoplastic cells.85 The resultant impaired surveillance may 
aggravate the oncogenic effects of environmental and genetic carcinogenic factors, 
enabling neoplasms to appear.85  
Second, many of the cancer types common after transplantation are related to 
oncogenic viruses: lymphomas linked to Epstein Barr virus, nonmelanoma skin 
malignancies possibly associated with papillomaviruses, and Kaposi sarcoma related 
to human herpes virus 8.85,86 In an immunocompromised state with depressed 
antiviral immune activity, such viruses may play an important catalytic role in 
progression towards malignancy.85  
Third, many of the immunosuppressive agents may also have intrinsic drug-
specific oncogenic properties unrelated to their immune-suppressive effect.79,87 For 
instance, cyclosporine inhibits DNA repair mechanisms, induces cancer-cell 
invasiveness, and promotes angiogenesis.87-90 Similarly, tacrolimus also promotes 
tumor progression,91,92 and azathioprine can cause chromosome breaks and nuclear 
abnormalities.87 On the other hand, mostly based on preclinical studies but 
increasingly also based on clinical evidence, mTOR inhibitors and MMF may 
themselves exhibit some antitumor activity.79,85,90  
Together with these oncogenic factors, chronic antigen attack from the graft and 
local inflammatory processes stimulate a partially depressed immune system, and 
with impaired feedback mechanisms, control over the degree of immune response 
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may fail. This, in turn, may lead to abnormal lymphoid proliferation, resulting in 
post-transplant lymphoproliferative disorder (PTLD).1,85  
PTLD is the designation of a heterogenic group of lymphoproliferative 
conditions (most frequently of B lymphocyte origin) with EBV in 80% of cases 
present in the malignant tissue.85,93 The term comprises a spectrum of states, ranging 
from benign polyclonal mononucleosis-resembling conditions to malignant 
monoclonal non-Hodgkin lymphoma, in which benign forms may progress to 
malignancy.93 The key underlying mechanism is an immunosuppression-induced 
inhibition of critical T lymphocytic control of B lymphocyte proliferation, which, in 
the setting of EBV reactivation, results in unrestricted lymphoid proliferation.93 
Lymphomas of T lymphocyte origin are, however, also possible.93 
 
Clinical regimens and trends  
Induction therapy. In contrast to other solid-organ transplantation, in which induction 
therapy with antibodies is frequently used to enhance immunosuppression 
immediately after transplantation, antibody induction therapy in LT mainly serves for 
delayed initiation of nephrotoxic CNIs in pre-existing renal failure.19,51,53,94 Induction 
therapies are, moreover, increasingly being evaluated as part of CNI- or 
corticosteroid-avoidance protocols, and antibody induction may facilitate reduction in 
the subsequent maintenance immunosuppression required.18,53,80,94-96 Some findings 
also point towards antibody induction as leading to a reduction in HCV recurrence.94 
Although European statistics on immunosuppression trends are unavailable, US 
data indicate increasing use of antibody induction (7% in 1994 and 21% in 2004), 
possibly reflecting US allocation policies which tend to favor LT candidates with pre-
existing renal dysfunction.53 In the USA, IL-2 receptor antibodies are today the 
favored preparations (11% of overall use), followed by polyclonal antibodies, while 
use of OKT3 37 and alemtuzumab is minimal.53 In Finland, various induction 
therapies have been used in randomized multicenter studies. In patients with 
hepatorenal syndrome, IL-2 receptor antibodies are now the preferred agents, and are 
used in conjunction with a CNI delay. 
Maintenance therapy. Although variations exist between centers regarding the 
specific agents used as well as the precise timing of their tapering and 
discontinuation, the standard maintenance regimen almost universally consists of 
either cyclosporine or tacrolimus, combined with corticosteroids and typically one of 
the antimetabolites.11,18,37,38,53,55 The standard Finnish protocol comprises 
cyclosporine, corticosteroids (methylprednisolone), and MMF (azathioprine until 
2006).  
Due to their well-known side-effects, the large doses of corticosteroids in the 
first postoperative days and weeks are usually rapidly tapered, with complete 
withdrawal generally attempted during the first year.37,55 In 2004, 80% of recipients 
were discharged on corticosteroids in the USA, with only 49% on steroids after 1 year 
and 33% after 2 years.53 Although steroid withdrawal proves safe in terms of survival 
and rejection, and beneficial in relation to reducing metabolic effects and 
cardiovascular complications,96 the emerging trend, evident in 20% of USA 
recipients,53 is toward completely steroid-free regimens. This, however, remains 
controversial.11,38,96 Patients transplanted for autoimmune conditions often need 
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higher doses of steroids, and HCV recipients benefit from steroid withdrawal in the 
long-term.1 
Based on US statistics and European single-center experience, the most recent 
decades demonstrate a gradual shift from cyclosporine+azathioprine-based 
combinations to tacrolimus+MMF-based protocols at many centers.11,37,53 The 
percentage of patients discharged from the hospital with an antimetabolite in the USA 
in 2004 was 58%, and 55% were using them at one year (52% MMF, 3% 
azathioprine).53 MMF seems as safe as azathioprine, and appears superior in 
preventing acute rejection.11,60 Although antimetabolites may be discontinued within 
1 year after LT,55 evidence is compelling that continuation of MMF reduces rejection 
rates, allows for lower doses of CNI, and may improve renal function and facilitate 
steroid withdrawal.11,37,60,96-99  
In the USA, 97% of recipients were discharged with a CNI (89% tacrolimus, 8% 
cyclosporine), and more than 90% were using CNIs at one year after LT.53 Debate is 
still ongoing and data somewhat conflicting regarding the optimal CNI agent. In 
cyclosporine- and tacrolimus-treated LT patients, survival appears  
comparable.57,66-70,100 Tacrolimus appears to offer the benefit of slightly lower rates of 
early rejection and early graft loss, less hypertension and hyperlipidemia, and less 
need for steroids, but study results are not entirely unanimous.57,66-70,100 The recently 
introduced prolonged-release form of tacrolimus, allowing once-daily dosing, will 
probably be superior in terms of patient compliance.101 Cyclosporine, on the other 
hand, has the advantage of being less diabetogenic and causing less gastrointestinal 
toxicity and may be more beneficial in HCV-infected patients.57,66-68,70,100,102 
As mentioned, the use of mTOR inhibitors in LT is still under evaluation. 
Emerging results, however, show their great potential, especially in reducing 
posttransplant cancer risk.61,65,103,104 The mTOR-inhibitor-based regimens, therefore, 
appear as an attractive alternative for HCC-transplanted patients.105,106 US data reveal 
that 5% of recipients had received sirolimus at the time of discharge in 2004, but, 
possibly reflecting the diminishing significance of wound-healing issues and hepatic 
artery thrombosis risk in later periods, up to 12% received sirolimus at one year.53 
In response to the toxicity in current regimens, a number of modified 
immunosuppression protocols have been and presently are being attempted, with 
particular emphasis placed on minimizing corticosteroids and CNIs.18,96 Novel 
approaches include modified regimens to reduce or avoid adverse effects, attempts to 
individualize therapy, and new drug-monitoring methods.11,12,14,18,54,55,96 The long-
desired possibility of inducing graft tolerance by selectively stimulating instead of 
suppressing the immune reaction, however, still remains a distant goal.49 
 Antirejection therapy. More than 90% of acute rejection episodes, affecting 18% 
of recipients in the USA, are reversed by either augmenting baseline 
immunosuppression or by employing a short course of corticosteroids, with no 
resultant detrimental effect on outcome.11,38,53,69,72 Steroid-resistant rejection is 
typically treated with antibodies, with ATG and OKT3 most frequently used in 2004 




OUTCOME AND SHORT-TERM COMPLICATIONS 
Survival rates  
Outcome after an intervention such as LT have a number of endpoints. The traditional 
endpoints: short-term patient survival (time from transplantation to death) and graft 
survival (time from transplantation to graft loss) now exhibit impressive lengthening 
(Figure 2 and 3). Among LT recipients, risk of death relative to that of the general 
population is, however, high, and although diminishing with longer follow-up, it 
remains elevated; a study from Birmingham107 reported standardized mortality ratios 
of 13.6 at 0 to 4 years, 3.7 at 5 to 9 years, 2.6 at 10 to 14 years, and 1.5 beyond 15 
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Figure 2. Patient and graft survival following liver transplantation in Europe. Reproduced by 
permission of the copyright owner (European Liver Transplant Registry).  
 
During recent decades, survival improvement has occurred particularly for 
patients transplanted because of hepatic malignancy, cirrhosis, or ALF, as well as for 
pediatric patients.11 The indications currently with the best survival rates in Europe 
are benign tumors and metabolic diseases, whereas malignant tumors, ALF, and HCV 
still generally show less good results.11  
Causes of mortality vary with time after LT; typically graft dysfunction and 
general causes predominate in the early period, infections gain importance in the 
intermediate period, and de novo and recurrent tumors, in addition to general causes, 
then become key contributors (Figure 4).  
Retransplantation due to graft loss – necessary in 10% to 15% of recipients – is 
in the first month chiefly the result of graft dysfunction or technical complications 
(hepatic artery thrombosis) and later mostly of disease recurrence or, infrequently, of 
chronic rejection.1,8 
 Another endpoint of increasing interest, particularly in the context of allocation 








Figure 3. Patient survival by era of liver transplantation in the Nordic countries. Reproduced by 
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Figure 4. Causes of mortality in relation to time after liver transplantation in Europe 1988 to 
2008. Adapted with permission of the copyright owner (European Liver Transplant Registry).  
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Quality of life 
With more and more patients surviving past their first few posttransplant years, 
outcome evaluation has increasingly emphasized employment and quality of 
life.11,21,22,108-111 Many immunosuppression-related side-effects and other LT-
associated chronic medical conditions with little or no impact on survival may 
markedly impair quality of life.11,21,112 This is of particular importance in pediatric 
patients, who are expected to survive for decades and who, at the time of LT, are still 
undergoing developmental processes.108,112,113 
Methodology. Quality of life in medical research generally refers to health-
related quality of life (HRQoL), a multidimensional construct reflecting the physical, 
psychological, and emotional dimensions of health.109-111,113 HRQoL may be 
measured by a variety of generic (non-disease-specific) instruments, including 
psychometric and utility measures, as well as disease-specific instruments.110 About 
100 HRQoL studies on LT patients exist, but meta-analyses and reviews in this area 
indicate that methodological differences severely limit comparison of results across 
studies.22,108-111,113 Single-center studies, on the other hand, are usually small, and 
subject to bias introduced by variable population characteristics.108 Quality of life 
studies are, furthermore, constrained by some inherent limitations; they exclude 
deceased patients and patients in very poor condition (such as ALF patients prior to 
LT), and quality of life is affected by cultural, economic, and social factors.22 
Impact of LT on HRQoL. Despite these limitations, several longitudinal studies 
note that the universally poor HRQoL of LT candidates significantly improves after 
LT at all ages.22,108-111,113-116 The largest gains are in physical functioning, with 
domains related to psychological health, social functioning, and sexual functioning, 
although generally improving, showing more discrepancies across studies.22,109-111,115 
Comparisons to healthy controls. The few studies comparing the HRQoL of LT 
recipients with that of healthy controls mostly indicate that the vast majority of 
patients experience a poorer HRQoL.22,109-113,117 In a recent meta-analysis, such 
inferiority was evident in all domains except for mental health and bodily pain.22 Data 
on HRQoL of long-term LT survivors are scarce,22,118-121 but indicate similar results 
as for shorter-term survivors. 
Predictors of HRQoL. Factors most consistently associated with impaired 
posttransplant HRQoL include pretransplant disease-severity, HCV, de novo disease 
(such as posttransplant diabetes), length of exposure to immunosuppression; the 
impact of age, gender, alcoholic liver disease, and ALF (etiologies other than ALF 
and alcoholic liver disease scantily studied) remains contradictory.22,108,112,113,116,121 
Economic aspects. Utility-based HRQoL measures allow calculation of quality-
adjusted life-years, in order to include HRQoL in cost-effectiveness analyses.109,110 
Cost and cost-effectiveness issues receive increasing emphasis nowadays, but such 
data on LTs are scanty.109,110 
 
Employment 
With an average age at LT of less than 50, adult recipients would be spending their 
days working. However, only 26 to 57% of recipients return to 
work.22,110,111,117,119,122,123 This wide range may depend on differing definitions of 
“employed,” on use of non-validated instruments, and on disparity in patient 
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population, sample size, and length of follow-up.22,109-111,122 Proposed predictors of 
post-LT employment include younger age, pretransplant employment and high 
income, private insurance, absence of pretransplant diabetes, good physical 
functioning, and higher general health score.22,117,122,123 Data on appropriate 
interventions to encourage return to work especially after LT, are unavailable. 
 
Short-term complications 
Improvement in survival times largely mirrors a reduction in common short-term 
complications such as vascular problems, acute rejection, biliary strictures and leaks, 
infections, and early toxicity from immunosuppressive agents (Table 
4).1,10,14,17,37,38,41,55,124-134  
 Infections. The majority of LT recipients experience one or more infections by a 
broad spectrum of pathogens. Infection is also a major cause of death in the first 6 
months (Figure 4).1,82 A predictable pattern of infection, has, in recent years, been 
drastically altered and its overall incidence reduced by antimicrobial prevention 
strategies and more judicious use of immunosuppressive agents.82 Common 
prevention protocols include vaccination, perioperative antibiotics and antifungals, 
antiviral prophylaxis or preemptive therapy, and anti-pneumocystis 
prophylaxis.1,17,37,55,82   
During the first postoperative month, surgery-related and postoperative care-
associated bacterial and fungal infections predominate (wound infections, intra-
abdominal infections, pneumonia, catheter infections, anastomotic leak- and stricture-
induced infections, clostridium colitis), but immunosuppression-induced exacerbation 
of a recipient’s pre-existing smoldering infection, herpes simplex infection, or donor-
derived infection (uncommon) may also occur.1,37,82  
Months 1 to 6 are typically characterized by residual effects of technical 
problems and earlier infections, infections with immunomodulatory viruses (CMV, 
EBV, HCV), and many opportunistic fungi (Candida, aspergillus, Cryptococcus) and 
bacteria.1,82 The widespread use of trimethoprim-sulfamethoxazole as anti-
pneumocystis prophylaxis has not only made pneumocystis infection rare, but has 
also reduced the occurrence of toxoplasmosis and many listeria and nocardia 
infections.17,82,135 Most transplant centers employ some form of prevention for 
CMV,17,82,136 and antiviral prophylaxis is associated with its 58 to 80% reduction.136 
Overall incidence of CMV disease within the first year is approximately 5%, a rate 
highly dependent on donor and recipient serologic status. Prophylaxis may delay its 
onset.136 Donor-acquired or reactivated CMV may manifest as fever, malaise, and 
cytopenias (CMV syndrome), or as tissue-invasive disease (most often involving the 
gut), but may also, through complex immunomodulatory properties, predispose to and 
interrelate with acute and chronic rejection, accelerated HCV recurrence, EBV-
associated PTLD, other opportunistic infections – and thus with reduced 
survival.82,136  
 Risk for infection begins to diminish at 6 months after LT, and infections in the 
long term resemble those of the general population; with community-acquired viral 
respiratory infections constituting up to 80%.82 Recurrent chronic viral hepatitis 
infection also becomes increasingly relevant.82 
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Table 4. The main noninfectious complications in early post-liver transplantation (LT).  
 Incidence in modern literature  
Typical time of 
occurrence after LT Impact on outcome 
Biliary complications (10-15% in large series) 
Anastomotic 
strictures 
3-9% <8 months When treated → usually no negative impact.
Nonanastomotic 
strictures 
3-15% Any time, on average 3-6 
months in large series 
Frequent need for repeated interventions. 
50% graft loss. 
Leakages 2-15% Predominantly <1 month If untreated → infection and  
                        abscess formation. 






~5% require surgery 
≤2 days Variable. Site of bleeding found in 50% of 
surgically explored cases 
Hepatic artery 
thrombosis 
~3% (0-7%) in adults,  
~8% (1-20%) in children 
~30% <1 month 
(typically ≤ 1.week),  
~70% >1 month 
Mortality rate: ~33% (12-60%) in adults,  
                       ~25% (0-80%) in children.  
Biliary complications common.  
Early-onset → usually reoperation + 
reanastomosis; 50-70% require re-LT.  
Hepatic artery 
stenosis 
~3-5% (difficult to 
ascertain) 




<3% Within weeks, but may 
occur at any time. 
If untreated → portal vein thrombosis and 
graft failure possible.  
Portal vein 
thrombosis 




0-2% Within weeks Variable. 
Rarities: aneurysms, vascular rupture, steal syndrome 
Rejection 
Acute 20-50% (heterogenous 
diagnostic criteria).  
Clinical rejection: ~30% 
Peak incidence 2.week, 
predominantly <3 
months 
Histological severity an important 
prognosticator. Mostly mild episodes with 
graft / patient survival generally unimpaired 
(even associated with improved long-term 
survival). 
Hyperacute Extremely rare Within hours Mortality approaching 100%. 
Graft-versus-host 
disease 
<1% <2 months Mortality rate: >70% in adults,  
                      ~35% in children.  
Graft not affected. 
Graft dysfunction   Note: variously defined  
Primary 
nonfunction 
4-7% Typically <3 days,  
by definition <7-10 days 




15-30% As above, but more 
elongated 
May recover with supportive therapy. Urgent 
retransplantation in progression to 
extrahepatic complications (hemodynamic 




Depends on the setting Immediately 50% mortality (sepsis) within 6 weeks. 
Other: Complications related to postoperative intensive care (cardiorespiratory problems, hemodynamic complications, 
electrolyte alterations, renal dysfunction, neurological complications) 
a Graft dysfunction due to insufficient functional liver mass 




In contrast to the short-term complications, for which incidences, risk factors, and 
treatment options are generally well known, corresponding data for long-term 
problems are only now emerging.  
 
Renal dysfunction 
Alhough renal dysfunction in the long-term usually manifests as chronic kidney 
disease (CKD), with gradually deteriorating renal function over months to years, 
acute kidney injury in the perioperative period may leave residual dysfunction as 
well.19 Although CKD occurs more frequently as follow-up lengthens, its precise 
incidence varies (4% to 80%) due to differing definitions, variable follow-up time, 
and differing methodology, population characteristics, and therapy.19,73,137-144 In a 
large population-based study comprising more than 36 000 LT patients, incidence of 
CKD – defined as a glomerular filtration rate (GFR) < 30 mL/min – rose from 8% at 
1 year to 18% at 5 years, and rose above 25% at 10 years.139  
 Etiology of CKD. Causes and risk factors for posttransplant CKD are partly 
intertwined and can be divided into pre-, peri-, and posttransplant conditions. In the 
pre-LT period, renal function may be impaired by kidney disease independent of the 
liver disease (as in the nontransplant setting), by disease-entities affecting both the 
liver and kidney (such as viral hepatitis-related glomerulonephritis, various toxins, 
and alcoholic cirrhosis-associated IgA nephropathy), or as a consequence of end-
stage liver disease (hepatorenal syndrome type I and II).145 In the perioperative 
period, acute kidney injury is reported in 17% to 95% of patients, and a severe form 
requiring renal-replacement therapy in 5% to 35%.1,19,73 Although in many cases 
renal function is subsequently regained, in other instances a variable degree of 
residual dysfunction may persist; hence contributing significantly to CKD.19,73,139  
Established risk factors for acute kidney injury in the LT setting include these 
pretransplant factors, severity of liver disease, hemodynamic instability, 
intraoperative bleeding, lack of use of the Piggyback technique, graft dysfunction, 
prolonged vasopressor use, infections, re-laparotomy, and drug toxicity (including 
CNIs).19  
Following the immediate posttransplant period, CKD may be attributed to CNIs 
via primary chronic nephrotoxicity as well as being secondary to CNI-induced 
hypertension and diabetes.1,12 Use of other nephrotoxic agents (certain antibiotics), 
drug interactions, and HCV recurrence may also contribute to CKD 
development.1,19,73 Risk factors that clinical studies most consistently note as 
associated with impaired long-term renal function, especially in the LT population, 
include high doses of CNI, pre-LT hepatorenal syndrome, pre-existing renal 
insufficiency, duration of pre-LT renal dysfunction, hypertension, diabetes, use of 
nephrotoxic drugs, postoperative acute kidney injury, postoperative renal-replacement 
therapy, HCV infection, and older age.19,137-140,142-144,146-148  
The relative importance of these causes and risk factors, however, remains 
somewhat obscure. Few studies have assessed etiology by means of renal 
biopsy.141,149,150 Whereas Fisher and colleagues,141 studying biopsies in severe renal 
dysfunction (creatinine > 250 µM/L), concluded that 77% of cases showed 
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histological findings suggestive of CNI nephrotoxicity, Pillebout and colleagues,149 
investigating 26 patients with GFR < 60 mL/min, noted lesions of a more 
multifactorial origin: CNI-related lesions were present in 46% of cases, but these 
often coincided with pathological changes attributable to other etiologies. More 
recently, O’Riordan and colleagues150 demonstrated results very similar to those of 
Pillebout. 
Measurement and definition of CKD. In a clinical setting, direct measurement of 
GFR – the gold standard for assessing renal function – is impractical and 
expensive.151 Creatinine concentrations are routine, but are increasingly being 
replaced by estimations of GFR through equations such as the Cockcroft-Gault 
equation or Modification of Diet in Renal Disease Study equations.151,152 Estimations 
of GFR in the cirrhotic patient are, however, usually inaccurate,152 and also in the LT 
recipient only ~65% of GFR estimates fall within 30% of the GFR measured 
directly.151 Recent National Kidney Foundation guidelines define CKD as GFR below 
90 mL/min or kidney damage, and end-stage renal disease (ESRD) as the need for 
renal-replacement therapy.153 
 Impact of renal impairment on outcome. Renal dysfunction, whether pre-existing 
or in the form of acute kidney injury or CKD, is associated with increased post-LT 
mortality and graft loss.19,73,139,154 Ojo and colleagues139 noted, among patients 
developing CKD after transplantation, a 4.55-fold mortality risk.  
 Management. Assessing the degree of reversibility of pretransplant renal 
dysfunction is imperative, because irreversible renal impairment may require 
combined liver-kidney transplantation.145,155 This may, however, be difficult since the 
generally reversible hepatorenal syndrome, for instance, can also become partially 
irreversible if prolonged, and the exact duration during which this transformation 
occurs remains unknown.145 Following LT, CKD-preventive strategies include 
appropriate management of hypertension and diabetes, as well as avoidance of 
nephrotoxic drugs.12 Antibody induction (mostly IL-2 or ATG) with delayed 
introduction of CNI is becoming established for patients with significant preexisting 
renal dysfunction18,19,53 and is undergoing trials as preemptive therapy in LT 
recipients with normal renal function.99 Following CKD, CNI reduction, with or 
without introduction of other immunosuppressants, is generally considered safe and 
efficient.18,19 In contrast, complete CNI avoidance, with conversion to (or initial) 
MMF- or mTOR inhibitor-based immunosuppression, appears to elevate risk for 
rejection.18,19 In advanced CKD, CNI reduction may not improve renal function.156 
Furthermore, both the optimal timing of CNI-reduction measures and means to 
identify those who will respond to such measures remain undefined.19 
 
Malignancy 
Posttransplant cancer may arise from donor-transmitted malignant cells – with 
different malignancies bearing different tumor-transmission rates1 – from recurrence 
of the recipient’s earlier malignancy, or from de novo cancer, the most common type. 
HCC leading to LT may, moreover, be related to posttransplant malignancy.1 The 
reported frequency of de novo cancer after LT ranges from 2 to 26%, depending 
mainly on follow-up but also on patients and methodology (as also for renal 
 33
dysfunction).12,157 Cumulative cancer incidence, taking into account unequal follow-
up times, increases to over 20% at 10 years (Table 5).158-165  
 
 




Any cancer Jonas et al,158 1997, Germany 458 15% 24% 21%
Haagsma et al,159 2001, The 
Netherlands
174 6% 20% 55% 52% 4%
Xiol et al,160 2001, Spain 137 13% 70% 10%
Herrero et al,161 2005, Spain 187 25% 39% 56% 11%
Finkenstedt et al,162 2009, Austria 779 10% 24% 32% 42% 17% 11%
Watt et al,165 2009, USA 798 12% 22% 54% 9%
Nonskin cancer Haagsma et al,159 2001, The 
Netherlands
174 2% 10% 33%
Xiol et al,160 2001, Spain 137 5%
Herrero et al,161 2005, Spain 187 11% 22%
Jiang et al,163 2008, Canada 2034 9%
Marqués Medina et al,164 2009, 
Spain
528 9% 18% 25%
Watt et al,165 2009, USA 798 7% 14%
Table 5. Studies reporting cumulative incidences of post-liver transplantation cancers
Proportion of cancers
9% at 8 years
Years
PatientsAuthor, year, countryCancer
26% at 8 years
 
 
Few series compare cancer incidences with age- and gender-matched controls, 
but those that do, report a 2.1- to 4.3-fold overall greater cancer incidence among LT 
patients (Table 6).107,159,161-163,166-168 Comparison with the normal population corrects 
some bias stemming from ethnic and demographic differences.157 Whereas 
nonmelanoma skin cancer and lymphoma (PTLD) are clearly the most common 
types, up to 70% and 45% of posttransplant cancers, uncertainty remains as to the 
incidence of other tumors.16,157 
Risk factors. Risk factors independently associated with overall de novo cancer 
development include age and underlying alcoholic liver disease.159-162,165,169-172 In 
addition, some have noted increased cancer risk related to ulcerative colitis or 
PSC,107,165 prolonged pre-LT immunosuppression,159 azathioprine (vs cyclosporine 
monotherapy),172 and rejection episodes.172 Such risk factors may, however, not apply 
for to tumor types, and some risk factors may predispose only to specific cancers.12 
Ulcerative colitis and PSC, for instance, predispose to colon cancer, and alcoholic 
liver disease to upper aerodigestive tumors.157 Data are inadequate regarding the 
influence of history of extrahepatic malignancy on its posttransplant recurrence.14,157 
PTLD. Most research focuses on the more neoplastic end of the PTLD spectrum 
(lymphoma), so that incidences of early benign processes which may progress to 
malignancy are seldom reported. One large registry study noted a cumulative 5-year 
incidence of post-LT lymphoma of approximately 1.5%.173 Pediatric populations 
show higher incidences – up to 15% – which mainly reflects children’s more frequent 
EBV-seronegativity.14 More than 80% of PTLDs are EBV-positive, and these occur 




Patients Overall SIR 
(95% CI)
Nonmelanoma 








Jain et al,166 
1998, USA






Sheiner et al,167 
2000, USA




3.2 (estimated) 28.6 (7.7-73.1) Not reported Not reported
Haagsma et al,159 
2001, The 
Netherlands




70.0 (28.1-144) Not reported Colon 12.5, kidney 
30.0
Breast, lung, Kaposi 
sarcoma
Oo et al,107   
2005, UK
1778 2.1 (1.7-2.4) 5.8 (4.3-7.6) 10.3 (6.1-16.2) Colon 4.9, lung 2.0 Breast, cervix, rectum
Herrero et al,161 
2005, Spain




16.9 (11.8-23.5) Not reported Not reported Not reported
Jiang et al,163 
2008, Canada













Not reported 13.8 (6.3-26.2) Kaposi sarcoma 144, 
esophagus 23.4, 
cervix 30.7, head and 
neck 7









Not reported 8.0 (4.0-14.2) Lung 3.1, esophagus 
8.3, oropharynx 4.8




Table 6. Studies comparing post-liver transplantation cancer incidences with those in the general 
population by standardized incidence ratios (SIRs)
 
 
more often localize in the graft, and are the dominant type in children.85,174 
Conversely, EBV-negative PTLD is distributed more evenly throughout a 10-year 
follow-up and may be related to higher mortality; some authors argue that this type 
may actually be a separate disease entity.85,174,175 The best established contributors to 
PTLD development are EBV-seronegative recipients (especially with EBV-
seropositive donors) and intense immunosuppression (especially use of OKT3 or 
ATG antibodies).93,157,173,175-177 
 A high viral load of EBV, HCV, or CMV infection, autoimmune liver disease, or 
alcoholic cirrhosis have also been implicated as predisposing to PTLD.176 The clinical 
presentation is broad – frequently with nonspecific symptoms – and extranodal 
involvement is common (up to 90% of PTLDs).85,93,173 Diagnosis requires 
histopathologic examination, and work-up includes extensive blood chemistry and 
serologic and radiologic assessment.17,85,93 Reducing immunosuppression is an 
integral part of treatment and is often sufficient for early lesions. Antiviral therapy 
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may be applied in EBV-positive PTLD, and in some cases anti-CD20 antibodies 
(rituximab), radiation, or chemotherapy.14,55,93 The ideal regimen, however, remains 
undefined. Furthermore, some evidence exists that anti-CMV immunoglobulin such 
as CMV prophylaxis may prevent early PTLD.178 
 Skin cancers. In LT recipients, the most frequent cutaneous malignancies are 
squamous cell and basal cell carcinoma.157,179 Squamous cell carcinoma tends to 
develop at a younger age, be more aggressive, and more often show multiple lesions 
than in the general population.14 Risk factors include intensity of immunosuppression, 
PSC, and hepatocarcinoma, and as also for the nontransplant population: older age, 
previous skin cancer, sun exposure, and fair skin.14,85,157,160,165,179 Treatment follows 
conventional practice, and re-evaluation of immunosuppression is, due to high risk 
for recurrence, also advisable.179 
 Other cancer types often observed with high frequency include colorectal, 
pulmonary, and oropharyngeal, plus Kaposi sarcoma (Table 6). Some series have, 
however, observed no such cases.157 Although cancer types common in the general 
population (breast, cervix, prostate) appear no more frequently in LT recipients, such 
cancers may occur at an earlier age, be more aggressive, and be linked to poor 
survival.157,162,180 The value of immunosuppression adjustment following the 
occurrence of nonskin, non-PTLD malignancies is unclear.55 
Impact on outcome. Haagsma and colleagues159 reported an overall cancer-
related risk of death of 2% at 5 years, 5% at 10, and 15% at 15 years. Survival is, 
however, closely related to tumor type; nonmelanoma skin cancer has little influence 
on survival (2-year survival after diagnosis close to 90%), whereas internal 
malignancies contribute significantly to mortality.12,15,159,161,162,181 Mortality from 
PTLD reaches 50%.173,175 
 Prevention and screening. The effect of avoiding risk factors such as smoking 
and sun exposure is accentuated in the LT population.12,55 CNI reduction or 
conversion to mTOR inhibitors may reduce cancer risk,182,183 but ensuing rejection 
episodes requiring heavy immunosuppression may eradicate any such benefit.85 
Which immunosuppression regimen is optimal in patients at high risk for 
posttransplant cancer remains unclear.85 Furthermore, no evidence-based screening 
protocol is defined for the LT population, although annual skin exams and strict 
adherence to standard screening guidelines are general recommendations.12,14,17,85 
EBV viral-load monitoring may aid in identification of patients at risk for PTLD.175 
Recent data reveal that the introduction of intensified posttransplant surveillance 
(including annual CTs and urologic, gynecologic, and dermatologic screening) 
improved survival.162 
 
Risk for cardiovascular disease 
By 10 years, LT recipients face a cardiovascular (CV) disease event rate of 24%,184 
and CV disease emerges as one leading cause of late mortality.8,185 Comparison with 
a matched general population confirms that LT patients have a 3-fold risk for CV 
events and a 2.6-fold risk for CV death.186 Apparently accelerated atherosclerosis 
may result mainly from an excess of traditional CV risk factors after LT;12,185,187,188 
recent studies report a post-LT prevalence of hypertension ranging from 49 to 77%, 
that of dyslipidemia from 27 to 62%, obesity from 22 to 47%, and diabetes from 9 to 
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57%.167,186,189-192 Glucose levels, blood pressure, and lipid levels are often transiently 
elevated in the early posttransplant period,193 but Sheiner and colleagues 167 observed 
that, among LT patients surviving more than 5 years, the standardized prevalence 
ratio (SPR), as compared with that of the nontransplant population, was 3.1 for 
hypertension, 6.0 for diabetes, 1.2 for obesity (non-significant), and 0.9 for 
hypercholesterolemia (non-significant). Other series have shown 22% of nonobese 
patients’ becoming obese within 2 posttransplant years.194 Numerous and partially 
interrelated variables contribute to this elevated CV risk-factor prevalence, including 
those of the nontransplant population and ones more specific to those with LT. The 
latter include immunosuppressive drugs for all risk factors, HCV and CMV infection 
for diabetes, and cholestatic liver disease for dyslipidemia.12,185,195  
Diabetes. The pretransplant cirrhotic state may itself induce hepatogenous 
diabetes, via peripheral and hepatic insulin resistance as well as via impaired insulin 
secretion.196 Such a form of diabetes – estimated to affect up to 60% of cirrhotics196 – 
has resolved in up to 67% following LT.197 In the early posttransplant period, 
surgery-related stress, high-dose corticosteroid and CNI therapy, infection, and 
parenteral nutrition often elicit transient hyperglycemia,185,198,199 which is also 
associated with elevated risk for overt diabetes later.195 On the other hand, as many as 
80% of diabetes cases sustained past the early post-LT period develop within 1 month 
post-LT.192  
Corticosteroids promote diabetes primarily by elevating both peripheral insulin 
resistance and gluconeogenesis stimulation, and to a lesser extent by impairing 
insulin secretion.200,201 This diabetogenicity appears to be dose-dependent; steroid 
dose reduction improves insulin sensitivity, although complete withdrawal from a low 
dose (prednisolone 5 mg/day) may perhaps offer no further benefit.201  
CNIs, on the other hand, predispose to diabetes through multiple mechanisms 
mutually resulting in suppression of pancreatic insulin secretion.200 These effects, 
which are more intense with tacrolimus,64 may in part reverse themselves following 
dose reduction.200,201 Diabetes has been associated with poorer post-LT prognosis: 
increased CV morbidity and mortality, more fatal infections, higher rejection rates, 
and impaired graft survival.192 
Immunosuppression-induced hypertension and dyslipidemia. Mechanisms 
underlying corticosteroid-induced hypertension include activation of the renin-
angiotensin system, increased responsiveness to catecholamines and angiotensin II, 
and reduced activity of vasodepressor systems.12 CNIs may cause hypertension 
through increased sympathetic and renin-angiotensin system activity, increased 
endothelin synthesis, and reduced nitric oxide-mediated vasodilatation, the net effect 
being vasoconstriction.12 CNIs promote dyslipidemia by inhibiting bile acid 26-
hydroxylase, thereby reducing bile acid synthesis from cholesterol and reducing the 
subsequent transport of cholesterol into the intestine. Moreover, cyclosporine binds to 
the LDL receptor, resulting in an elevated serum LDL level (Table 2).202 
Other CV risk factors. Of LT recipients, 17% in one series were active 
smokers.203 Renal failure has been recognized as an independent CV risk factor,188 
but little data exist on other CV risk factors in this population. 
Management. The efficacy of conventional CV risk-reducing interventions has 
not been specifically confirmed in the LT population, but given the convincing data 
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from the nontransplant population, many authors advise the extrapolation of common 
guidelines to LT recipients.12,14,55,185 The recommended management of 
posttransplant diabetes follows the same principles as for type 2 diabetes.12,204 
Assessment of overall CV risk using scoring systems such as SCORE or Framingham 
has been applicable to the LT population.205 Evidence points to the particular benefit 
of calcium-channel blockers, as they may counteract CNI-induced renal 
vasoconstriction, and also to the benefit of drugs suppressing the renin-angiotensin 
system, which is activated by CNIs.74 Hypercholesterolemia may, in addition to 
accelerated atherosclerosis, be associated with chronic graft rejection,185 and likewise 
the possibilty exists that statins have a rejection-opposing effect.206 
 Adjustment in immunosuppression. Steroid-free regimens safely improve 
glycemic control, blood pressure levels, and the lipid profile, and they support 
weight-loss efforts.12,55,96,207 A similar benefit is achieved by introducing 
mycophenolate in conjunction with CNI dose reduction.12 Regarding other 
modifications, substituting one agent with another often modifies the risk-factor 
profile in favorable and unfavorable directions (Table 2).12,185  
 
Other nonhepatic complications  
Osteoporosis. In addition to risk factors recognized in the nontransplant population, 
end-stage liver disease (especially of cholestatic origin), corticosteroids, and CNIs 
contribute to posttransplant bone-mass loss, which is most profound 3 to 6 months 
after LT.12,208 By 2 years after LT, the cumulative incidence of fracture is 24% to 
55%; thereafter the fracture risk diminishes, because average bone mineral density 
typically improves.12,208,209 The recommended management parallels that in the 
nontransplant population.12,55 
Other long-term complications. Pharmacotherapy after LT conveys the potential 
for a wide spectrum of chronic conditions and symptoms in the long term. Among 
long-term survivors, the reported prevalence of neurologic complications (mostly 
polyneuropathies) ranges from 6 to 11% and of cataract from 8 to 24%, and 
occurrence of peptic ulcer disease is approximately 5%.167,184,210  
Nonadherence. Long-term complications, side-effects, and the high cost of 
medication, as well as attitudes of adolescents pose a threat to adherence to the 
medical regimen, which may subsequently worsen outcome.211 Poor adherence may 
be difficult to detect and even more difficult to manage.211 
 
Hepatic complications 
Disease recurrence. Recurrence of the primary liver disease is a leading cause of 
graft failure following the first posttransplant year,8 even though diseases tend to 
recur with highly variable frequency. HCV and HCC recurrence have the highest 
clinical relevance (Table 7).14,17,55 Detection of recurrence is often hampered by 
coexistence of overlapping histological changes attributed to transplant-related factors 
such as rejection or ischemic biliary complications, and by the poor diagnostic utility 


















Finland,      
1982-200823
Primary biliary cirrhosis ++ + 71% 78%
Primary sclerosing cholangitis ++ ++ 70% 83%
Autoimmune hepatitis ++ + 66% 90%
Alcoholic liver disease + + 61% 63%
Hepatitis C +++ +++ 55% 82%a
Hepatitis B + (with 
prophylaxis)
+ 69% N.A.
Hepatocellular carcinoma + (when within 
Milan criteria)
- 47% 44%
a 7-year survival (n=13)
Abbreviations: N.A., not available  
 
 
Chronic rejection. Chronic rejection injures the vascular endothelium and bile 
ducts, manifesting clinically as increasing cholestasis.212 Occurring at any time after 
LT, it is overall considered a rare event – with current incidence estimates of less than 
3% among adults and approximately 10% in children. It is almost always preceded by 
acute rejection.213 Early chronic rejection may respond to additional 
immunosuppression; other cases require retransplantation.55,213  
Biliary complications. Although late biliary complications, sometimes resulting 
in chronic graft dysfunction, may be the sequelae of earlier biliary problems, 
nonanastomotic biliary strictures in particular may also emerge during longer-term 
follow-up in as many as 15% of recipients.14,126,127 Any injury to the biliary 
epithelium, including hepatic artery thrombosis, preservation injury, and prolonged 
ischemia, can contribute to the development of such strictures, but immunologic 
factors entailing rejection, CMV, and PSC, predominate as the cause for strictures 
appearing in the long term.126,127 Strictures – frequently discovered by cholestatic 
liver tests or recurrent cholangitis – may often be treated by endoscopic dilatation and 
stenting.14,126,127 Occasionally they require surgery, however, and if graft failure 
develops, retransplantation.14,126,127 
 Other complications. Chronic graft dysfunction may, in addition to those 
conditions above, occasionally result from chronic hepatitis, de novo fibrosis or 
cirrhosis, and various vascular, drug-induced, and viral causes.214 The clinical 
relevance of such complications remains uncertain.214  
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Aims of the study 
The overall aim of this thesis was to investigate the long-term effects of liver 
transplantation on major long-term nonhepatic complications and on quality of life as 
compared with an age- and gender-matched Finnish general population, and also its 
effects on employment status. 
 
The specific objectives were to evaluate: 
 
1. In adult patients after liver transplantation, their renal function and the cumulative 
incidence of chronic kidney disease (I). 
 
2. In adult patients transplanted for acute liver failure, their prevalence of 
cardiovascular risk factors (IV).  
 
3. Among all Finnish liver transplant patients, the occurrence of cancer (II). 
 
4. Among all adult Finnish liver transplant patients alive, their quality of life and 
employment status (III). 
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Patients and methods 
PATIENTS AND GENERAL STUDY DESIGN 
Consecutive patients undergoing LT at Helsinki University Hospital were included 
(Table 8). With commencement of the Finnish LT program in 1982, all adult liver 
transplantations in Finland have been performed at the Surgical Hospital of Helsinki 
University Hospital. The patients also make regular scheduled follow-up visits at the 
same clinic. In addition, if any graft problems ensue, investigations and treatment are 
performed at the clinic, with follow-up data from local hospitals sent to the transplant 
center at least twice annually. 
 End-points of follow-up were the end of each study. In Study I, the other end-
points were development of ESRD or retransplantation. In Study IV, is was the fifth 
posttransplant year. Children (aged under 17) were included only in Study II. For 
other exclusion criteria, see Table 8.  
 
 
I II III IV
Issue addressed Renal dysfunction Malignancy Quality of life, 
employment
Cardiovascular risk
Time-period for transplantation 1982-2004 1982-2005 1982-2007 1987-2004
Number of patients included 396 540 353 77
Method of patient recruitment Consecutive Consecutive Consecutive Consecutive
Retransplanted patients included No Yes Yes Yes
Children included No Yes Adults transplanted 
as children
No
Other exclusions Prior organ 
transplantation     
(1 kidney)
- Deceased patients 
(n=273)










Control group No Finnish Cancer 
Registry; matched 












weighted to reflect 
age and gender 
distribution 
Follow-up endpoints June 2004 December 2005 June/July 2007





5 years after 
transplantation 
(February 2009)
Table 8. Features of study design
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Ethical approval for Study III came from the ethics committee of the Helsinki 
and Uusimaa Hospital district, and all patients also signed an informed consent form. 
Studies II and IV received approval from the National Institute for Health and 
Welfare. 
Study I assessed renal function at different posttransplant time-points, as well as 
possible changes in renal function after LT and the frequency distribution of different 
stages of renal dysfunction. Subgroup analyses were performed by indication group 
(CLD, ALF, or liver tumor), and further according to renal function at listing for LT, 
according to time period of LT, and according to the MELD score at LT. Patients 
who developed CKD or ESRD underwent a more detailed review. 
Study II evaluated the cumulative incidence of malignancies after LT, with 
occurrence of malignancies compared to an age-, gender-, and calendar-time-matched 
Finnish general population. Potential LT-related risk factors for development of 
cancer also assessed comprised transplant indication, initial CNI agent, acute 
rejection, antibody therapy, retransplantation, and CMV status. Identical analyses 
were performed separately for development of lymphoma, skin cancer, and other 
cancer types. Among patients who developed any posttransplant malignancy, 
assessment included method of cancer detection and outcome after cancer. 
Study III sought to reveal the HRQoL and employment status of LT recipients, 
to compare the HRQoL of patients with that of the general population, and to 
investigate LT-related factors possibly influencing posttransplant HRQoL and 
employment. 
Study IV evaluated incidence of hypertension, dyslipidemia, weight gain, and 
diabetes following LT for ALF, and compared the 5-year posttransplant CV risk 
factor prevalence with equivalent data from the general population. The accumulation 
of CV risk factors in relation to age, as well as possible LT-related predictors of CV 
risk were also relevant, as was occurrence of CV disease before or during the study 
period. 
 
CLINICAL PARAMETERS AND DEFINITIONS 
Background clinical, laboratory, and demographic data, comprising age, gender, time 
of LT, liver-disease diagnosis, and immunosuppression regimen came from the 
prospective Finnish liver transplant registry, patient records, and the hospital’s 
laboratory database. In addition, Studies II and IV included data on acute rejection 
episodes and treatment with monoclonal or polyclonal antibodies. Study I, moreover, 
included data on waiting times for LT, preoperative renal-replacement therapies, and 
MELD score, while Study II incorporated data on CMV status, and Study IV on 
steroid use and degree of graft steatosis. This was defined as steatosis present in more 
than 30% of hepatocytes in time-zero liver biopsy before liver implantation. MELD 
scores were calculated according to the official equation9 by use of laboratory 
parameters obtained on the day of transplantation (I); no diagnosis-based exception 
points were given, and in the case of a creatinine level exceeding 350 µmol/L 




Renal function was assessed as plasma creatinine and urea at the following time-
points: at listing, day of transplantation, at worst value during the first postoperative 
week, and annually thereafter.  
For a better estimation of GFR, creatinine clearances were calculated at these 
same time-points, with patients’ weights also recorded. Creatinine clearance was 
calculated by the Cockcroft–Gault formula,215 by which GFR = (140-age) × weight 
(kg) / a × plasma creatinine (μmol/L), where a is 0.8 for men and 0.95 for women. 
Renal function was classified into stages according to recommendations of the 
National Kidney Foundation.153 According to these guidelines, stage 1 is GFR ≥90 
mL/min (normal renal function), stage 2 is GFR 60 to 89 (mild decrease), stage 3 is 
GFR 30 to 59 (moderate decrease), and stage 4 is GFR ≤29 (severe decrease). In this 
study, ESRD was defined as either GFR <15, or initiation of dialysis, or need for 
kidney transplantation. CKD was defined as stage 4 renal dysfunction or ESRD 
lasting at least 6 months. 
 
Malignancies 
Data regarding cancers among patients and controls came from the Finnish Cancer 
Registry. The cohort of Study II was compared with the national population register. 
The correct personal identification number and data on vital status were achieved for 
every cohort member. All residents of Finland since 1 January 1967 have a unique 
personal identification code used in all the major registers in Finland. Follow-up for 
cancer through the files of the population-based Finnish Cancer Registry was 
automatic, via the personal identifier as a key. Follow-up for cancer started at the date 
of the first transplant, and ended at death or on 31 December 2005, whichever came 
first. A further division was time elapsed since LT. In sub-analysis among patients 
with acute rejection, follow-up for cancer started at the date of rejection. 
The numbers of cases and person-years at risk were counted, by five-year age 
groups, separately for four calendar periods (1982-1987, 1988-1993, 1994-1999, and 
2000-2005). The expected numbers of cases for all cancers combined and for specific 
cancer types were calculated by multiplying the number of person-years in each 
gender and age-group by the corresponding cancer incidence rate in all of Finland 
during the period of observation. The specific cancer types a priori selected for 
analysis included cancer sites with a known or suspected exceptional risk in earlier 
studies, and other common cancer types. This provides the entire picture of the cancer 
situation among Finnish LT patients. 
 
Cardiovascular risk factors and disease 
Data collected. CV risk factor variables collected were body mass index (BMI) and 
medications for hypertension, dyslipidemia, and diabetes, as well as history of 
coronary heart disease, cerebrovascular disease, and peripheral vascular disease. 
These data were collected at the time of listing to LT as well as at 5 years 
posttransplant. Furthermore, fasting plasma/serum concentrations of glucose, total 
cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, triglycerides, and glycated hemoglobin (HbA1c) were determined 
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at 5 years post-LT. No data on corresponding blood levels at the time of listing were 
collected; because ALF alters lipid and glucose levels considerably, these would have 
been unreliable markers of previous cardiovascular risk.216  
Blood pressure levels were not recorded due to the lack of any prospectively 
planned and standardized protocol of blood pressure measurement. Blood pressure 
levels sporadically available in this retrospective setting involve multiple sources of 
error and were thus disregarded. Use of antihypertensive medication, conversely, was 
based on multiple measurements and clinical practice guidelines, and can therefore be 
regarded as a more reliable marker of hypertension. Antihypertensive drugs included 
were beta-blockers, diuretics, angiotensin-converting-enzyme inhibitors, angiotensin-
II inhibitors, calcium-channel blockers, centrally acting antihypertensives, and a 
combination of these.  
Antidiabetic drugs comprised insulin and oral antihyperglycemic agents. Lipid-
lowering drugs comprised statins, fibrates, and cholesterol-absorption inhibitors. Data 
on cardiovascular diseases before and after LT as well as cause of death were 
collected for patients dying earlier than 5 years after LT. 
Definitions of CV risk factors. In accordance with World Health Organization 
criteria,217 diabetes was defined as a fasting plasma/serum glucose of 7.0 mmol/L 
(126 mg/dL) or above, or use of antidiabetic medication. Impaired fasting glucose 
(IFG) was defined as a fasting plasma/serum glucose between 6.1 and 6.9 mmol/L 
(110 and 125 mg/dL) and no antidiabetic medication.  
For the purpose of this study, dyslipidemia was defined as a fasting 
plasma/serum cholesterol of 5.0 mmol/L (190 mg/dL) or above, or a LDL level of 3.0 
mmol/L (114 mg/dL) or above, or a HDL level of 1.0 mmol/L (38 mg/dL) or less, or 
a triglyceride level of 2.0 mmol/L (176 mg/dL) or above, or medication for 
dyslipidemia.  
Hypertension was defined as use of antihypertensive medication. Overweight 
was defined as BMI 25-30 kg/m² and obesity as greater than 30 kg/m². In analyses on 
difference in risk factor prevalence before and after LT, definitions of hypertension, 
dyslipidemia, and diabetes were based solely on use of medication at these two 
separate time-points. 
 
HRQoL and employment assessment 
HRQoL was assessed with the 15D questionnaire, mailed for self-administration to 
all patients alive in June 2007, along with a prepaid envelope for its return. 
Questionnaires were in each patient’s native language, Finnish or Swedish, the two 
official languages in Finland. The letter also included a questionnaire for assessment 
of employment status and a consent form which the patients were asked to sign and 
return. A reminder went in July 2007 to those who did not respond to the first letter. 
Strict confidentiality was ensured, and in order to obtain truthful responses we 
stressed that their transplant physicians would have no access to answers from any 
individual patient. Letters were returned to a department unassociated with the 
transplantation center (Helsinki and Uusimaa Hospital Group, Group Administration) 
and responses were registered by persons uninvolved in analyses of the results. 
15D. HRQoL was measured by the 15D instrument,218 a generic, 15-
dimensional, standardized and self-administered measure of HRQoL which can serve 
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both as a profile and a single-index score measure.218,219 Its 15 health dimensions are: 
moving, seeing, hearing, breathing, sleeping, eating, speech, elimination (urination 
and defecation), usual activities (keeping up with work, studies, household activities, 
and leisure activities), mental function, discomfort and symptoms, depression, 
distress, vitality, and sexual activity.  
For each dimension, the respondent must choose from one of five levels that best 
describes his or her present health status (the best level being 1 and the worst, 5). The 
valuation system of the 15D is based on application of the multi-attribute utility 
theory. A set of utility or preference weights obtained from the general public through 
a 3-stage valuation procedure generates the utility score, i.e., the 15D score (single 
index number), over all the dimensions on a 0 to 1 scale (1 = no problems in any 
dimension, 0 = deceased), and dimension level values on a 0 to 1 scale.219 The 
minimal clinically important difference in 15D score is ≥0.03.219 In most of its 
important properties, the 15D compares favorably with similar instruments.218,220 
If a respondent leaves up to three questions unanswered, the missing data may be 
imputed by regression models taking responses on the other dimensions as well as 
age and gender as explanatory variables, according to 15D instructions.218 
Employment status and working capacity. A categorical and descriptive 
evaluation of patients´ current employment status and the subjective impact of LT on 
their working capacity was assessed with five questions: 
 
1. Are you currently in working life (yes or no)? 





d. Early retirement for a cause associated with my liver disease. 
d. Early retirement for a cause not associated with my liver disease. 
e. Other cause (what?). 
3. How soon after your transplantation were you able to return to work? 
a. Less than 3 months. 
b. 3-6 months. 
c. 6-12 months. 
d. 1-2 years. 
e. >2 years. 
f. Work not resumed. 
4. If the answer to the previous question was option f, then choose one of the following 
alternatives: 
a. Retirement at required age before transplantation. 
b. Retirement at required age shortly after transplantation. 
c. Studying before transplantation. 
d. Unemployed before transplantation. 
e. Early retirement after transplantation for a cause associated with my liver 
disease. 
f. Early retirement after transplantation for a cause not associated with my liver 
disease. 
g. Other cause (what?). 
5. How do you estimate your current working capacity and functional capacity in everyday 
life compared to that at 1 week before transplantation? (The respondent must choose 1 to 5 




Control data from the Finnish general population for Studies III and IV came from 
the National Health 2000 Health Examination Survey. This survey, conducted in 
2000 and 2001, is because of its careful study design and 93% participation rate 
considered to accurately and validly represent the entire adult Finnish population.221 
Those individuals in the age range of the LT recipients and for whom necessary 
comparison data were available were selected; in Study III controls comprised 6050 
individuals and in Study IV 6483. 
 In Study III, the control sample was, for the purpose of analysis, weighted to 
reflect patients’ age and gender distribution.  
 In Study IV, comparisons between patients and controls were adjusted for age, 
gender, and area of residence, because CV risk factor prevalence in the Finnish 
general population shows considerable variation in these factors. 
 Study II obtained control data from the Finnish Cancer Registry. The cancer 
registration system in Finland is virtually complete,222 and the computerized record 
linkage procedure precise,223 thus providing unbiased control data and accurate 
comparisons for the study. 
 
IMMUNOSUPPRESSION 
All patients received CNI–based initial immunosuppression. The majority received 
cyclosporine in combination with azathioprine and methylprednisolone. Only a few 
patients, those participating in controlled clinical trials, had tacrolimus-based initial 
immunosuppression. Furthermore, some immunologically unstable patients – 
particularly patients presenting with a recurrent early acute rejection episode after 
steroid-treated acute rejection, and patients with late acute rejection episodes – were 
converted from cyclosporine to tacrolimus. MMF was added for some patients with 
CNI-induced nephrotoxicity, and CNI doses were subsequently reduced or 
withdrawn. For a few patients participating in controlled studies, MMF during the 
study period also served as the initial antimetabolite, instead of azathioprine.  
The initial target of cyclosporine concentration was 200 to 250 ng/mL, tapered 
over time to maintain a level of 70 to 150 ng/mL. For tacrolimus, respective values 
were 15 to 20 ng/mL and 5 to 10 ng/mL.  
All acute rejection episodes were histologically confirmed. The initial treatment 
regimen included a 5-day steroid course (methylprednisolone 3 mg/kg/day) with 
steroid-resistant rejections treated with OKT3 monoclonal antibodies or in some 
cases with ATG polyclonal antibodies. Antibodies – consisting of ATG and, since 
2000, with IL-2 receptor antibodies – were also administered to some patients as 







Data were analyzed with StatView for Windows (SAS Institute, Inc., Cary, NC, 
USA) statistical software (I), or SPSS statistical software version 14.0 (SPSS, Inc., 
Chicago, IL, USA) (II, III, IV). In general, the Chi-Square test served for categorical 
variables, whereas survival functions and cumulative incidence rates were calculated 
by the Kaplan-Meier method. Differences in survival between groups were tested by 
the log rank test.  
Study I applied the unpaired t-test or Mann-Whitney test as appropriate for 
comparing two groups, with the Kruskal-Wallis test for comparing three groups. The 
paired t-test or when appropriate the Wilcoxon signed-rank test served to test 
differences within a group across time-points. Correlations between laboratory 
parameters were calculated with the Spearman correlation. 
Study III analyzed differences in mean 15D score between groups by use of the 
independent samples t-test or a 1-way analysis of variance as appropriate. The same 
study reports the differences in means between groups as well as their 95% 
confidence intervals (CI) for the main results. 
The standardized incidence ratio (SIR) for cancers was calculated by dividing 
observed number of cases by the expected number (II). Similarly, SPRs for CV risk 
factors were calculated as the observed case prevalence in the patient population at 5 
years after LT divided by the expected cases in the general population (prevalence in 
general population Χ patient population size) (IV). The expected prevalence was 
counted in 5-year age groups adjusted for gender and the five university hospital 
districts according to patient’s geographical area of residence. The 95% CIs for the 
SIRs and SPRs were calculated assuming a Poisson distribution of cases. The SPR 
was statistically tested by the z-test. 
Potential LT-related risk factors for the development of cancer were considered 
in a Cox proportional hazards model adjusted for age, gender, and time since 
transplantation. The same analysis was also done separately for development of 
lymphoma, skin cancer, and other cancer. 
In Study III, subgroup analyses were performed by age, gender, survival time, 
transplant number, and employment status. These subgroups were considered in 
separate linear regression models, with the 15D score as the dependent variable and 
age, gender, and the respective subgroup variable as independent variables. Another 
test was whether any linear or inverted U-shape relationship existed between HRQoL 
and survival time; this was tested by including both survival time and its square as 
explanatory variables in the respective linear regression model. The LT population 
was further combined with the age- and gender-standardized sample of the general 
population in order to test whether the HRQoL of the different transplant indication 
groups (CLD, ALF, or liver tumor) would deviate from that of the general population. 
This test computed a linear regression model adjusted for current age and gender, 
where each of the three LT indication groups were coded with a different indicator 
variable, and the general population served as the reference. 
Relative risk ratios were calculated for variables possibly associating with CV 
risk factors (IV). 
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P values <0.05 were considered statistically significant. However, to test whether 
significant differences existed between LT patients and the general population on the 
individual 15D dimensions according to the independent samples t-test, and 
simultaneously adjusting for multiple testing, the Bonferroni correction was used 




POPULATION CHARACTERISTICS AND SURVIVAL 
Baseline and posttransplant characteristics of the patients included in the studies are 
shown in Table 9. Average age at LT was somewhat lower in Study II due to the 
inclusion of children, whereas the higher proportion of female patients was even more 
accentuated in the ALF population (IV).  
 
 
I II III IV
Study Renal 
dysfunction




Patients, n 396 540 353 77
Time period of transplantations 1982-2004 1982-2005 1982-2007 1987-2004
Age at transplantation, mean (SD) 48 (11) 43 (18) 48 (13) 46 (12)
Gender, male:female 42:58% 45:55% 42:58% 30:70%
Decade of transplantation
1980s 9% 8% 6% 6%
1990s 54% 49% 36% 55%
2000s 37% 43% 58% 39%
Liver transplantation diagnoses
Chronic liver disease 70% 73% 73%
Primary biliary cirrhosis 34% 26%
Primary sclerosing cholangitis 22% 19%
Alcoholic cirrhosis 15% 14%
Viral cirrhosis 3% 4%
Other 26% 38%
Acute liver failure 23% 18% 22% 100%
Unknown etiology 63% 62%
Other known etiology 12% 13%
Acute Budd-Chiari 10% 9%
Drug-related 10% 11%
Toxic (nondrug) 5% 5%
Liver tumor 7% 8% 5%
Hepatocellular carcinoma and cirrhosis 45%
Hepatocellular carcinoma without cirrhosis 35%
Other liver malignancies 20%
Preoperative dialysis 15%
Days on preoperative dialysis, mean (SD) 10 (17)
MELD score at transplantation, mean (SD) 20 (11)
History of nonhepatic malignancy 2%
Initial calcineurin inhibitor agent
Cyclosporine 82% 86%
Tacrolimus 17% 14%
Acute rejection 52% 52%
Monoclonal/polyclonal antibody therapy 12% 20%
Retransplantation 9% 7% 16%
Steroid use at 5 years 42%
Methylprednisolone dose at 5 years, mean (SD) 2.9 mg (1.4)
Patients with graft steatosis 17%
Abbreviations: MELD, model for end-stage liver disease
Table 9. Patient characteristics
 
 49
Of 401 LT recipients still alive in 2007, 356 (89%) returned the HRQoL and 
employment questionnaires (III). Three of the responders were excluded because they 
omitted more than three answers on the 15D; thus 353 patients were included in the 
final analyses (Table 9). Patients who underwent LT as children were more likely to 
be nonrespondents than were older patients, as shown by 13% of nonresponders’ 
belonging to this group versus 5% among responders. In other features, responders 
and nonresponders did not differ significantly. 
During the period from 1982 to 2007, overall patient survival rates were 90% at 
1 year, 82% at 5 years, 72% at 10, and 59% at 20. Corresponding graft survival rates 






















Figure 5. Patient and graft survival after liver transplantation at Helsinki University Central 
Hospital between 1982 and 2007. 
 
Less than 10% of all LTs were performed during the 1980s (Table 9). With time, 
a noticeable improvement in survival rates emerged (Figure 6). Most of this 



















2001 – 2005, n = 206
2006 –, n = 138
1991 – 1995, n = 137
1996 – 2000, n = 135 
1982 – 1990, n = 64
 
Figure 6. Patient survival by time-period of liver transplantation in Finland. 
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 CLD and ALF patients displayed significantly better survival than did liver 
tumor patients (P = 0.001 between groups) (Figure 7). 
  Average waiting times for LT, as reported in Study I, were 42 days for the 
CLD group, 5 for the ALF group, and 31 for the liver tumor group. Of ALF patients, 
40% required dialysis prior to LT, as compared to 8% of CLD patients and 3% of 
liver tumor patients. 
 
 
Figure 7. Patient survival according to indication group in Finland. 
 
 Compared with other indication- and age groups, retransplantation was more 
often necessary in ALF patients (see Study I, Table 1, p. 3) and in children (see Study 




Pattern of renal function 
Average blood concentrations of cyclosporine and tacrolimus decreased steadily 
during follow-up; mean (SD) cyclosporine levels in ng/mL were 184 (82) at 1 year, 
159 (63) at 3 years, 143 (41) at 5, and 122 (35) at 10; mean tacrolimus levels were 
10.7 (7.6) at 1 year, 9.2 (5.1) at 3 years, and 7.7 (3.9) at 5. 
Average creatinine level increased slightly, but nonetheless statistically 
significantly, from that before LT to that at 1 year among all patients combined and 
among CLD patients (Table 10). Among liver tumor patients, the increase was even 
more pronounced, whereas ALF patients showed the opposite trend of a lower mean 
creatinine level after LT than before. During the first postoperative week, average 
creatinine levels were significantly higher than were pretransplant levels in all groups 
(P < 0.0001), except the tumor group. Creatinine levels at the first-week time-point 
also differed significantly between the three indication groups (P = 0.0002), with a 
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significant difference, moreover, appearing between the CLD and ALF groups at 
listing (P = 0.02). 
Average GFR at different time-points demonstrated similar patterns of renal 
function (Table 10; see also Study I, Table 3, p. 3), except in the ALF group, where 
decreasing mean GFR levels, pre- to posttransplant, contradicted the improved renal 




Table 10. Levels of creatinine (μmol/L) and estimated GFR (mL/min) at different 
time-points for all patients, and separately for chronic liver disease, acute liver 
failure, and liver tumor. Levels expressed as mean (SD).  
  At listing LT day First week 1 y 10 y 
All patients, n 396 395 394 327 52 
Creatinine 100 (87) * 106 (81) * 166 (112) 109 (50) 102 (32) 
Estimated GFR 99 (50) * 94 (55) *  76 (29) 70 (23) 
Chronic liver disease, n 277 276 276 235 41 
Creatinine 91 (73) * 96 (60) * 155 (104) 108 (48) 100 (33) 
Estimated GFR 98 (46) * 91 (43) *  76 (30) 71 (23) 
Acute liver failure, n 90 90 88 71 9 
Creatinine 137 (122) N.S. 143 (126) N.S. 210 (131) 107 (55) 115 (32) 
Estimated GFR 97 (62) *** 101 (86) ***  76 (28) 64 (23) 
Liver tumor, n 29 29 29 21 2 
Creatinine 75 (20) ** 80 (25) ** 145 (93) 121 (45) 87 (11) 
Estimated GFR 111 (38) * 105 (35) *  75 (24) 70 (-) 
Abbreviations: LT day, day of liver transplantation; First week indicates highest creatinine values 
recorded for each patient during the first posttransplant week. 
* P<0.0001, ** P<0.001, *** P<0.01; N.S., non-significant (comparisons with 1-year levels).  
Adapted with permission of the publisher, John Wiley & Sons, Ltd.  
 
 
Stages of renal dysfunction over time. Figure 8 illustrates the relative frequency 
distributions of the stages of renal dysfunction at different times – excluding patients 
already on dialysis. The incidence of stage 4 (severe) renal dysfunction at listing was 
4.8% among all patients, 2.2% for CLD, 14.6%, ALF, and 0% for the tumor group. 
During follow-up, a steadily increasing proportion of patients with either stage 3 or 4 
(moderate or severe) dysfunction appeared among all patients and among CLD 
patients. 
In the ALF group, a significant reduction (P = 0.005) occurred in the incidence 
of stage 4 renal dysfunction from the listing date to 1 year after LT. No other groups 
exhibited a similar reduction. In the tumor group, stage 4 renal dysfunction did not 
occur at listing or at 1 year, but at 3 years, an incidence of 10% had already emerged, 





Incidence and etiology of renal disease 
A total of 25 patients (6% of all patients) developed CKD. During the study period, of 
these 25, 7 progressed to ESRD. This resulted in a cumulative incidence of CKD of 
1.8% at 1 year, 9.7% at 5 years, and 15.7% at 10. Likewise, the cumulative incidence 
of ESRD rose from 0.3% at 1 year to 1.8% at 5 years and 3.3% at 9. CKD appeared 
on average at 4.3 years after LT (range 0 to 10 years), whereas ESRD appeared on 
average at 5.6 years (range 0.2 to 9.6 years). 
Overall, 20 (7%) of CLD patients developed CKD, compared with 4 (4%) of 
ALF patients and 1 (3%) of liver tumor patients. Of these, progression to ESRD 
























GFR ≥90 54,2 45,4 25,6 21,9 18,9 24,0
GFR 60-89 23,2 28,3 41,6 42,3 39,2 24,0
GFR 30-59 17,8 19,6 28,9 32,7 34,5 44,0
GFR ≤29 4,8 6,6 3,9 3,1 7,4 8,0
At listing LT day 1 y 3 y 5 y 10 y
A) Estimated GFR(mL/min/1.73m²), 




















GFR ≥90 53,6 44,0 24,1 19,4 15,2 21,1
GFR 60-89 25,7 32,0 42,3 47,2 38,4 26,3
GFR 30-59 18,5 19,6 28,6 30,6 38,4 47,4
GFR ≤29 2,2 4,4 5,0 2,8 8,0 5,3























GFR ≥90 49,4 44,9 31,3 26,2 29,0 33,3
GFR 60-89 18,0 15,7 37,3 33,3 45,2 16,7
GFR 30-59 18,0 23,6 29,9 38,1 22,6 33,3
GFR ≤29 14,6 15,7 1,5 2,4 3,2 16,7
At listing LT day 1 y 3 y 5 y 10 y





















GFR ≥90 75,0 60,7 22,2 40,0 40,0 0,0
GFR 60-89 14,3 32,1 50,0 10,0 20,0 0,0
GFR 30-59 10,7 7,1 27,8 40,0 20,0 0,0
GFR ≤29 0,0 0,0 0,0 10,0 20,0 0,0
At listing LT day 1 y 3 y 5 y 10 y
D)
 
Figure 8. Relative frequency distribution of estimated GFR at different time points among the 
total group (A), chronic liver disease (B), acute liver failure (C), and liver tumor (D) groups. 
Patients on continuous post-transplant dialysis excluded. Reproduced by permission of the 
publisher, John Wiley & Sons, Ltd. 
 
Four of the seven ESRD patients underwent renal biopsy; in other cases, renal 
diagnosis was based on clinical evaluation. In four cases (57%), the main cause for 
ESRD was chronic CNI toxicity (supported by biopsy results in three cases), and one 
patient each had pre-existing IgA nephropathy (biopsy confirmed), or polycystic 
kidney degeneration along with antibiotic toxicity, or an uncertain diagnosis due to 
multiple predisposing factors (diabetes mellitus, hypertension, and CNI toxicity). At 
the end of follow-up, two of the ESRD patients remained in dialysis, two had 
received a kidney transplant, and three had died without kidney transplantation. 
Dialysis commenced in all patients prior to kidney transplantation. 
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Influence of various factors on posttransplant renal function 
Pre- and early posttransplant renal function. Patients were stratified in two 
subgroups based on their GFR at listing: either <60 (90 patients; 23%) or ≥60 (306 
patients; 77%) mL/min (Figure 9). After LT, renal function deteriorated in patients 
with good pretransplant GFR; in contrast, it improved among patients with poor 
pretransplant estimated GFR. The difference between subgroups remained significant 
for up to 5 years after LT (Figure 9). 
 In the CLD population, the number of patients with a GFR <60 mL/min at 
listing was 57 of 277 (21%) and in the ALF population 30 of 90 (33%). Figure 10 
illustrates posttransplant changes in mean GFR among the pretransplant GFR-
stratified CLD and ALF groups. Patients in the tumor group were excluded from this 
stratification because they were too few. Of patients with a poor pretransplant GFR, 
73% (32 of 44 patients) remained with a GFR less than 60 mL/min at 1 year in the 
CLD group. By contrast, only 35% (8 of 23) of ALF patients remained with a GFR 
less than 60 mL/min. The respective results at 5 years were 76% (19 of 25) of CLD 




























At listing LT day 1 y 3 y 5 y 10 y
>=60
<60
Estimated GFR at listing
Time points
* *
* * ** N.S.
 
Figure 9. Stratification of all patients based on GFR at listing (< or ≥60 mL/min), and 
subsequent mean GFR in these two subgroups. Vertical lines depict ± 1 standard deviation.  

























At listing LT day 1 y 3 y 5 y 10 y
>=60, Chronic Liver Disease
<60, Chronic Liver Disease
>=60, Acute Liver Failure
<60, Acute Liver Failure
Estimated GFR at listing
Time points  
Figure 10. Stratification of chronic liver disease and acute liver failure patients based on the 
GFR at listing (< or ≥60 mL/min), and subsequent mean GFR in these subgroups. Reproduced 
by permission of the publisher, John Wiley & Sons, Ltd. 
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Parallel to these figures, the correlation between GFR at listing and later GFR was 
strongest in the CLD group, whereas GFR at 1 year correlated well with long-term 
renal function in all groups (Table 11).  
Five of the 58 patients (9%) who had required pretransplant dialysis developed 
CKD posttransplant, resulting in a relative risk for CKD of 1.5 (95% CI 0.6-3.7). On 
average, CLD patients required longer renal-replacement therapies prior to LT than 
did ALF patients; mean time on pretransplant dialysis was 16 days for CLD and 5 
days for ALF patients.  
 
 
GFR 1 year 3 years 5 years 10 years
At listing All patients 0.54 * 0.51 * 0.43 ** 0.50 **
Chronic liver disease 0.63 * 0.62 * 0.54 ** 0.63 **
Acute liver failure 0.35 ** 0.27 n.s. 0.26 n.s. 0.43 n.s.
Liver tumor 0.49 *** 0.72 *** 0.31 n.s. -
1 year All patients 0.86 * 0.81 ** 0.73 **
Chronic liver disease 0.86 * 0.79 ** 0.75 **
Acute liver failure 0.85 * 0.88 ** 0.79 ***
Liver tumor 0.99 ** 0.96 ** -
Table 11. Correlations between GFR at listing and at 1 year after 
transplantation with subsequent GFR levels.
* P  < 0.0001, ** P < 0.01, *** P  < 0.05, n.s., non-significant  
 
 
Of the 25 patients who later developed CKD, at listing 36% had stage 3 renal 
dysfunction and 12% stage 4. At 1 year, 84% had either stage 3 or 4. 
MELD. The MELD score on the day of LT correlated rather poorly with later 
renal function (see Results in Study I, p. 6). Notably, however, among patients with a 
MELD score of 25 or less, renal function deteriorated more sharply following LT, 
approaching that of patients with MELD above 25 (see Study I, Figure 4, p. 7). 
Era of transplantation. Patients transplanted in earlier eras of LT presented with 
poorer mean GFR, but steepness of loss of renal function posttransplant was greater 






During a posttransplant follow-up of 3222 person-years in the cohort of 540 LT 
recipients, 39 de novo cancers developed in 36 patients. An additional 11 cases of de 
novo basal cell carcinoma of the skin also occurred. Of the 540 patients, 420 (74%) 
were alive at the end of follow-up.  
  The cumulative incidence of posttransplant de novo cancer was 3% at 1 
year, 5% at 5 years, 13% at 10, and 16% at 20 (Figure 11). The respective cumulative 
risk for de novo cancer-related mortality was 0%, 1%, 2%, and 2%. 
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In comparison with the general population, the overall SIR was 2.59 (95% CI 
1.84-3.53; Table 12). In addition to basal cell carcinoma – not included as cancer in 
overall SIR – non-Hodgkin lymphoma and non-melanoma skin cancer were the only 
cancer types to show significantly elevated SIRs (Table 12). Non-melanoma skin 
cancer included Kaposi sarcoma and squamous cell carcinoma. For nonsignificant 
SIRs see Study II, Table 2, p. 1432. In addition to the cancer types preselected for 
SIR analysis, we observed one each of urinary bladder, ovarian, and uterine cancers, 




Figure 11. Cumulative incidence of de novo cancer and de novo cancer mortality following 
liver transplantation. Recurrence of pretransplant cancer not included. Reproduced by 




Table 12. Standardized incidence ratio (SIR) with 95% confidence intervals (CI) for all
cancer cases and cases with significant SIRs among Finnish liver transplant patients,
1982-2005. 
 
Primary site  Observed     Expected     SIR       95% CI 
ALL CANCERS        39    15.1     2.59     1.84-3.53 *    
Non-Hodgkin lymphoma 8      0.57    13.9     6.01-27.4 * 
Skin, nonmelanoma 10     0.26    38.5    18.5-70.8 * 
Basal cell carcinoma of the skin 11     2.97     3.70     1.85-6.62 * 





Influence of various factors on posttransplant cancer occurrence 
Gender. A higher SIR appeared in males (SIR 4.16, 95% CI 2.61-6.30) than in 
females (SIR 1.74, 95% CI 1.01-2.78). Furthermore, of eight non-Hodgkin 
lymphomas, six occurred in males, producing a markedly higher non-Hodgkin 
lymphoma SIR for males (SIR 26.7, 95% CI 9.79-58.1) than for females (SIR 5.72, 
95% CI 0.69-20.7). Conversely, SIRs for nonmelanoma skin cancer were similar for 
males (SIR 36.2, 95% CI 9.87-92.7) and females (SIR 40.2, 95% CI 14.8-87.5).  
Age. The SIR was more elevated in children (SIR 18.1, 95% CI 2.19-65.5) than 
in adults (SIR 5.77, 95% CI 1.87-13.5 for those aged 17-39 and SIR 2.27, 95% CI 
1.55-3.20 for those ≥40). The SIR for non-Hodgkin lymphoma was 123 (95% CI 
3.12-686) at ages <17, 55.7 (95% CI 6.74-201) at ages 17 to 39, and 9.42 (95% CI 
3.06-22.0) at ≥40. Of 10 nonmelanoma skin cancer cases, nine occurred among the 
oldest transplant patients (≥40 at LT), the SIR for this group being 36.1 (95% CI 
16.5-68.5). 
Follow-up period. SIRs were further calculated according to posttransplant 
follow-up period, namely <2 years, 2 to 9 years and ≥10 years. Here, SIRs were 
higher in the earlier follow-up periods (see Study II, Table 3, p. 1432). All non-
Hodgkin lymphomas and nervous system cancers (all meningeomas) detected 
occurred before 10 years posttransplant, whereas nonmelanoma skin cancers occurred 
quite uniformly during each of the follow-up periods. 
Pretransplant cancer. Prior to LT, 55 patients each had a preexisting liver tumor, 
and another 11 had a history of nonhepatic malignancy. These 11 comprised 3 colon 
cancers, and 1 each of lymphoma, ventricle carcinoid, rectal cancer, pancreatic 
cancer, spinocellular skin cancer, medullar meningeoma, rectal carcinoid with 
metastasis to the liver, and thymoma with later HCC. None of these 11 patients 
developed de novo cancer posttransplant. The average time from detection of 
pretransplant malignancy to LT was 6.8 years (range 0.3-20.6 years). 
Indication. The 113 ALF patients had somewhat higher SIR (3.35, 95% CI 1.61-
6.16) than did patients with CLD (381 patients, SIR 2.39, 95% CI 1.58-3.48) or liver 
tumor (46 patients, SIR 2.47, 95% CI 0.30-8.92). This difference between groups 
was, however, not statistically significant in age-, gender-, and follow-up-adjusted 
hazards ratio statistics (Table 13, see also Study II, Table 4, p. 1433). 
Immunosuppression. Cyclosporine was used in 441 patients (82%) as the initial 
CNI agent. In this group, 36 of the 39 cancers (92%) were detected after LT. The 
cyclosporine group also produced 10 times more patient-years of follow-up than did 
the tacrolimus group: 2938 patient-years versus 276 patient-years. The overall SIR 
for patients with cyclosporine as their initial agent, as compared to that of the general 
population, was 2.61 (95% CI 1.83-3.61). Cancer sites that showed significantly 
increased SIRs in this group were non-Hodgkin lymphoma (SIR 13.36, 95% CI 5.37-
27.5), non-melanoma skin cancer (SIR 41.79, 95% CI 20.04-76.84), and basal cell 
carcinoma (SIR 4.06, 95% CI 2.03-7.26). The overall SIR for patients with tacrolimus 
as their initial agent was 2.32 (95% CI 0.48-6.79), compared to the general 
population’s. In the tacrolimus group, no cancer site showed significantly increased 
SIRs. 
Rejection. Those who had experienced one or more acute rejection episodes (276 
patients) had a lower SIR (1.77, 95% CI 0.95-3.02) than did those who had 
 57
experienced no rejection (261 patients, SIR 3.52, 95% CI 2.39-5.27). Furthermore, 
compared to the group of patients without rejection, the group with a history of a non-
antibody-treated acute rejection was associated with a relative cancer risk estimate of 
0.41 (P = 0.02) (Table 13). 
Antibody therapy. Antibody therapy for acute rejection did not alter cancer risk 
significantly. Of 276 patients with acute rejection, 47 (17%) had been treated with 
mono- or polyclonal antibodies. The SIR value for this group (1.71, 95% CI 0.35-
4.98) was similar to the SIR value for those who had not been treated with antibodies 
(SIR 1.79, 95% CI 0.86-3.29). Antibody induction therapy, on the other hand, raised 
the relative risk for cancer 4.3-fold (P = 0.004) (Table 13) and the relative risk for 
skin cancer 6.0-fold (P = 0.01) as compared to that of patients not treated with 







Chronic liver disease 1.00 (reference)
Acute liver failure 1.20 (0.54-2.66)






Yes, no antibody 0.41 (0.19-0.88)
Yes, antibody treatment 0.45 (0.14-1.50)
Mono-/polyclonal antibody therapy
No 1.00 (reference)
Yes, for acute rejection 0.72 (0.22-2.37)
Yes, induction therapy 4.32 (1.61-11.6)
Retransplantation 0.84 (0.25-2.78)
Cytomegalovirus status
Donor -  Recipient - 1.00 (reference)
Donor +  Recipient - 1.81 (0.21-15.9)
Donor -  Recipient + 0.97 (0.13-7.36)
Donor +  Recipient + 0.77 (0.09-6.61)
Bold figures highlight significant levels (P < 0.05).
Adapted with permission of the publisher, John Wiley & Sons, Inc.
Table 13. HRs for development of cancer after liver 
transplantation, according to Cox proportional hazard 
analysis adjusted for age, gender, and time since 
transplantation. 





Cancer detection and outcome 
Average time from LT to detection of cancer was 61 months (range 4-172 months), 
and 80% of posttransplant cancers were detected at ages 45 to 74 years. All 8 
lymphomas appeared at less than 7 years from LT; on average at 3 years. 
Posttransplant noncutaneous cancer developed in 25 patients. In retrospective 
examination of their patient records, cancer was detectable during routine follow-up 
in only three of these cases. The one case of breast cancer was detected during routine 
mammography, the rectal cancer during protocol colonoscopy for the patient’s 
ulcerative colitis, and the fibrosarcoma during a routine visit to the physician. The last 
patient underwent intensified follow-up due to unclear cause for hypersedimentation 
and hematuria. The remaining 22 patients had cancer detected after investigations of 
symptoms. 
Of the 36 patients who developed posttransplant cancer, 14 died by the end of 
follow-up; of these 14 patients, 7 died due to de novo malignancy, 5 due to solid 
organ tumor (1 each, ovarian, pancreatic, rectal, brain lymphoma, and prostate), and 2 
of PTLD. The 7 remaining patients died from causes not directly related to their 
cancer: one died of fungal infection 2 months after being diagnosed with Kaposi 
sarcoma, 2 died of kidney failure, and one each of cerebral infarction, myocardial 





CARDIOVASCULAR RISK FACTORS 
Cardiovascular risk factor incidence 
Of the 91 consecutive ALF patients, 14 died prior to the 5-year time point. Of these 
14, 3 were on preexisting antihypertensive medication and 1 had preexisting diabetes, 
but none were diagnosed with pre- or posttransplant CV disease. 
Final analyses, therefore, included 77 ALF patients. For prevalence of CV risk 
factors before and 5 years after LT see Table 14. 
A general trend toward weight loss emerged at the two time-points. 
Hypertension increased 6-fold, and the proportion of patients on lipid-lowering 
medication or with diabetes more than doubled (Table 14). The 5-year post-LT 
incidence of new-onset hypertension was 68% (46 of 68 patients), of new-start use of 
lipid-lowering medication, 7% (5 of 74 patients), of new-onset diabetes, 7% (5 of 74 
patients), and of new-onset obesity, 5% (3 of 59 patients). Furthermore, by 5 years 
after LT, 92% of patients presented with at least 1 of the 4 CV risk factors 
(overweight/obesity, hypertension, dyslipidemia, or IFG/diabetes); the average 
number of CV risk factors being 1.9 (SD 1.0). The sum of CV risk factors increased 
with age (see Study IV, Figure 2, p. 5).  
In comparison to the age-, gender-, and residence area-adjusted Finnish general 
population, the prevalence of hypertension at 5 years after LT was 2.73-fold that 
expected (Figure 12). In contrast, the prevalence of dyslipidemia was 31% less than 
expected, while overweight and obesity deviated nonsignificantly from the expected. 
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Diabetes tended to be more prevalent among LT recipients, although not significantly 
so, whereas IFG was significantly less common. When added together, the number of 
observed cases (diabetes+IFG) was 10 and expected cases 11.  
 
 
Table 14. Number of patients with cardiovascular risk factors 






Overweight (BMI 25-30 kg/m²) 30 (39) 25 (32) 
Obesity (BMI >30 kg/m²) 15 (19) 10 (13) 
Antihypertensive medication 9 (12) 55 (71) 
Lipid-lowering medication 3 (4) 7 (9) 
Diabetes 3 (4) 8 (10) 
Type 2 diabetes 2 (3) 7 (9) 
Oral antihyperglycemic medication 1 (1) 1 (1) 
Insulin 2 (3) 6 (8) 
Combination of oral agents and insulin 0 (0) 1 (1) 
Percentages are proportion among all 77 patients. 
Abbreviation: BMI, body mass index. 
Adapted with permission of the publisher, Lippincott, Williams & Wilkins.  
 
  
Cardiovascular disease incidence 
Three patients of the study population had a history of preexisting CV disease before 
LT: two patients had coronary artery disease with a history of coronary artery bypass 
graft surgery, and one had a history of transient ischemic attack, an acute myocardial 
infarction, and paroxysmal atrial fibrillation. Within 5 years after LT, an additional 
two patients were diagnosed with CV disease, including one with atrial fibrillation. 
The other patient underwent percutaneous transluminal coronary angioplasty and 
stenting 6 months after LT, and coronary artery bypass graft surgery 3 years after LT, 
and, moreover, was diagnosed with non-ST-elevation myocardial infarction 5 years 
after LT. Both patients had hypertension and dyslipidemia post-LT, one was obese, 
but neither had diabetes. 
 
Influences upon posttransplant cardiovascular risk 
The initial CNI used (tacrolimus or cyclosporine), steroid use at 5 years, history of 
retransplantation, history of acute rejection, antibody therapy, and graft steatosis were 
individually tested by calculation of relative risk ratios, for any association with the 
appearance of new-onset hypertension, diabetes, dyslipidemia, or overweight/obesity. 
Of these variables, the only statistically significant associations were between 
antibody therapy and hypertension (relative risk 1.49, 95% CI 1.15-1.94) and between 
antibody therapy and diabetes (relative risk 6.43, 95% CI 1.18-34.9) (see Study IV, 
Table 3, p. 5). 
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0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0
Risk factor                 Observed    Expected                       SPR (95% CI)
Overweight                 25                 29.53                         0.85 (0.55-1.25)                     
Obesity                        10                 17.39                   0.58 (0.28-1.06)                       
Hypertension             55                 20.16                                                                        2.73 (2.06-3.55)
Dyslipidemia              47                 68.02                      0.69 (0.51-0.92)
  
    Cholesterol ≥ 5        40                 62.47                     0.64 (0.46-0.87)                       
  
    LDL ≥ 3                    31                  56.19                  0.55 (0.37-0.78)
  
    HDL ≤ 1                    5                   11.47                0.44 (0.14-1.00)
  
    Triglycerides ≥ 2     13                 15.22                          0.85 (0.45-1.46)                         
 
    Medication               7                    5.32                                       1.31 (0.53-2.71)
Diabetes                     8                     4.21                                                    1.90 (0.82-3.74)                                           
    
IFG                               2                     6.92             0.29 (0.04-1.00)                       
















0.040   
 
Figure 12. Observed and expected numbers of cases with risk factor present, and 
standardized prevalence ratios (SPR) with 95% confidence intervals (CI), among the 77 
patients 5 years after liver transplantation. N.S., not significant. Reproduced by permission of 





QUALITY OF LIFE OUTCOMES AND EMPLOYMENT 
HRQoL compared with that of the general population 
On average, LT recipients demonstrated 15D scores similar to those of the matched 
general population (Table 15). Although this difference was statistically significant, it 
did not reach the level of 0.03 that is considered clinically relevant (Table 15). In the 
individual HRQoL dimensions, LT recipients exhibited statistically significantly 
lower 15D scores on the dimensions of moving, elimination (urination, defecation), 
usual activities (keeping up with work, studies, household activities, leisure 
activities), and sexual activity (Table 15; see also Study III, Figure 1, p. 68). 
Conversely, LT patients displayed higher 15D scores on the dimension of discomfort 
and symptoms. The groups did not differ significantly on the other dimensions. 
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Liver transplant patients, 
mean (SD)
General population,     
mean (SD)
Difference in mean levels 
between groups (95% CI)
Overall 15D score 0.889 (0.103) 0.907 (0.089) 0.018 (0.007-0.029)




Usual activities 0.066 (0.044-0.088)
Sexual activity 0.045 (0.020-0.070)
Higher mean scores for patients:
Discomfort and symptoms 0.037 (0.014-0.059)
A difference of 0.03 between groups regarding the mean 15D overall score is considered clinically relevant.





Various influences upon posttransplant HRQoL 
Age and gender. When adjusted for patient’s age at the time of the study, gender had 
no significant effect on 15D scores. Conversely, a small but statistically significant 
decline in 15D scores occurred by age (regression coefficient -0.001, 95% CI -0.002-
0.000), when adjusted for gender. Age at LT, on the other hand, did not influence 
15D scores significantly, when adjusted for current age and gender (regression 
coefficient -0.000, 95% CI -0.002 – 0.003).  
Retransplantation. A history of retransplantation altered 15D scores 
nonsignificantly in age- and gender-adjusted analysis (regression coefficient -0.029, 
95% CI -0.073 – 0.014). 
Follow-up period. Patients who had undergone LT less than 1 year prior to the 
study reported worse 15D scores than did patients with a longer time since 
transplantation (see Study III, Figure 2, p. 67). Conversely, patients at 1 to 5 years 
since LT exhibited the highest 15D scores. Mean 15D scores did, however, 
subsequently decrease gradually over time (see Study III, Figure 2, p. 67). With 
current age and gender standardized, a slight inverted U-shape relationship between 
HRQoL and survival time after LT remained, but this relationship was insufficiently 
robust to be statistically significant (see Study III, Table 2, p. 68). Nor was the 
coefficient of linear survival time significant (-0.001, 95% CI -0.003-0.002). 
Indication. On average, CLD-, ALF-, and liver-tumor patients exhibited similar 
15D scores, respectively, 0.892 (SD 0.101), 0.883 (SD 0.102), and 0.877 (SD 0.131). 
When compared with the age- and gender-standardized general population, however, 
the ALF group deviated somewhat more from the expected 15D scores than did CLD- 
or liver-tumor patients (Table 16).  
 
Employment status and working capacity 
A third of all patients at the time of the study were employed (see Study III, Table 3, 
p. 69), and their proportions did not differ by indication: percentages were 36% in the 
CLD, 34% in the ALF, and 32% in the tumor groups. Among the 64% of patients 
unemployed, the majority (56%) were unemployed due to early retirement, whereas 




Linear regression coefficient (95% CI) P
General population reference
Chronic liver disease -0.011 (95% CI -0.021 to -0.001) 0.04
Acute liver failure -0.024 (95% CI -0.042 to -0.005) 0.01
Liver tumor -0.012 (95% CI -0.050 to 0.026) 0.54
 Table 16. Deviation in 15D scores by indication group from that 
expected in the age- and gender-adjusted Finnish general 




At the time of the study, 268 patients were of working age (20 to 65 years old). 
Of these 268, 119 (44%) were employed, and these patients displayed both 
statistically and clinically significantly better 15D scores when adjusted for age and 
gender, than did working-age patients who were unemployed,. The difference in 
average 15D score between these two groups was 0.07 (95% CI 0.05-0.10). 
Although 43% of patients had returned to work after LT (see Study III, Table 3, 
p. 69), a return to work displayed an apparent age-dependent trend, with younger LT 
patients being more likely to return to work (Figure 13). Younger patients were also 
more often able to return to work after LT in less than 6 months (Figure 13). 
Comparison of indication groups revealed that a larger proportion of the 258 
CLD patients returned to work in less than 6 months, 46 (18%), than of the 76 ALF 
patients, 8 (11%). The difference between these proportions (0.07, 95% CI -0.03-
0.15) was, however, nonsignificant. Liver-tumor patients were excluded from 
analysis due to their small number. 
Despite the finding that less than half the patients had returned to work after LT, 
87% of recipients experienced better working/functional capacity than experienced 
one week before LT (Table 17). In CLD and ALF patients, proportions were similar: 
90% and 81%, but in liver-tumor patients the proportion was significantly less: 72% 
(P = 0.012). None of the patients transplanted at ages 20 years or less reported that 
their working/functional capacity at the time of the study had deteriorated compared 
to that before LT. In the two other age-groups, proportions of patients reporting 
improved working/functional capacity were similar: among the 168 aged 20 to 50, 
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Figure 13. Percentages of liver transplant (LT) patients who returned to work after LT 
according to age at time of LT. Only working-age patients included (20-65 at LT). Proportions 
inside the columns show how soon after LT they had returned to work. Reproduced by 





Table 17. Patients’ estimation of their change 
in working/functional capacity from that at 1 
week before liver transplantation to that at the 
time of the study.  
 n Answer 
Much better 258 77%
Slightly better 32 10%
Unchanged 19 6%
Slightly worse 15 4%





Studies I to IV reveal, in a retrospective and partly cross-sectional fashion, the 
frequency of renal dysfunction, cancer, and cardiovascular risk, as well as the quality 
of life and employment status, following LT. These studies include virtually all LT 
patients transplanted in Finland and alive up to 25 years from LT, with only one 
patient lost to follow-up. The single-center setting, the intensive follow-up protocol 
by the transplant center, and the prospective national liver transplant registry, 
moreover, provide precise demographic and clinical data relevant for analyses. Major 
drawbacks, however, include the retrospective design, which does not allow reaching 
with certainty conclusions on the associations found. For instance, declining renal 
function or rising blood pressure, glucose, or lipid levels may call for adjustments in 
the patient’s pharmacotherapy, but this is difficult to ascertain retrospectively. 
Subgroup analyses were, moreover, in part limited by inadequate statistical power, as 
evidenced by their width of confidence intervals. Where results were nonsignificant, 
the chance of a type II statistical error must be kept in mind.  
The principal strengths of the studies include the precise data obtained from a 
comprehensive cohort of patients at many time-points. In Studies II, III, and IV, an 
additional advantage is the accurate comparisons with age- and gender-matched 
controls who accurately represent the Finnish general population as a whole. 
Renal function measurement. Assessing renal function in end-stage liver disease 
patients and in LT recipients is challenging, due to the inaccuracy of all commonly 
used parameters.151,152 Direct measurement of GFR by methods such as inulin 
clearance – the gold standard – is impractical and expensive and has not been used at 
our center. The most practical estimation of GFR is achieved by creatinine-based 
formulas. Although the Modification of Diet in Renal Disease Study equation has 
recently demonstrated slightly better accuracy than the Cockcroft–Gault equation 151 
and has been used in many of the recent studies,137,139,224,225 the latter was our choice 
in the present study due to its wide use in clinical practice. 
Cardiovascular risk factors. In addition to the potential bias resulting from 
defining hypertension solely by use of medication, the study ignored some of the 
other CV risk factors such as tobacco use and family history. 
HRQoL assessment. Any quantification of quality of life is noninformative if 
subjects are not compared to a reference population. To permit such a comparison, we 
chose a generic HRQoL instrument. The excellent availability of reference data from 
the Finnish general population made the 15D instrument best. The lack of studies 
utilizing this instrument, however, hampers comparison of HRQoL results to those in 
other series. With a response rate exceeding 88%, the representativeness of the patient 
population was excellent, and the sample is considered of a size achieving sufficient 
statistical power for reliable comparison with controls. As in all of the other series in 
this field, bias naturally results from the exclusion of deceased patients. 
Employment assessment. The reliability of the employment results are limited by 
the ad hoc nature of the questionnaire as well as by definition issues: Part-time versus 
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full-time employment or whether patients returned to their original work and salary 
level were not distinguishable.   
Cumulative incidence. Incidence of the complications studied is largely 
dependent on length of time after transplantation, so actuarial incidence rates among 
patients with differing follow-up times are noncomparable across studies. One means 
of enabling comparison across studies for dichotomous endpoints such as CKD and 
cancer is by calculating cumulative incidence rates. CV risk factors, however, are 
often transient, particularly in the early posttransplant period, and assessing 
cumulative incidence is thus less suitable. To adjust both for follow-up time and for 
early transient disruptions in blood pressure, glucose, and lipid levels, the point 
prevalence of CV risk factors at 5 years after LT required assessment. 
Control data for the studies were generally precise and reliable. Study IV, 
however, risked bias because whereas patient data were collected during 1992 to 
2008, control data were collected during 2000 to 2001. The results in that study 
therefore do not account for population trends in the prevalence of CV risk factors 
between 1992 and 2008.  
Standardized ratios (SIR and SPR) and regression analyses allow for reliable 
comparison of two populations of markedly different size, and also compensate for 
any differences in gender- or age distribution between populations. In Study IV, 
comparison was further matched for area of residence, because the prevalence of CV 
risk factors in Finland exhibits considerable local variation. Prevalence of actual 
cardiovascular disease was not compared to that of the general population because 
reliable comparison would likely necessitate a follow-up longer than 5 years to avoid 




INCIDENCE OF LONG-TERM NONHEPATIC COMPLICATIONS  
Renal dysfunction. Many studies have employed diverse definitions of renal 
dysfunction and CKD,140,141,143,144 and this severely hampers interpretation and 
comparison of results. The Kidney Disease Outcomes Quality Initiative Guidelines 
have recently developed a widely acknowledged GFR-based classification,153 the one 
adopted in the present study.  
The cumulative incidence of CKD was 10% at 5 years and 16% at 10 years, 
almost half that observed by Ojo and colleagues139 in their review of 36 849 LT 
patients in the USA. By applying an equivalent definition of CKD, they reported a 
cumulative incidence at 5 years following LT of 18% and at 10 years, of above 25%. 
A single-center study from Ireland,224 on the other hand, reported a 10-year 
cumulative incidence of severe renal dysfunction (GFR <30 ml/min) of 7%, whereas 
single-center reports from the USA have found 5-year cumulative incidences of CKD 
from 8%137 up to 22%.225 Because the latter study was performed in the era after 
implementation of MELD-based organ allocation, more prevalent pretransplant renal 
impairment emerges as one potential explanation for their higher posttransplant CKD 
incidence. The variation in reported cumulative incidences may also be explained by 
differing population characteristics; in the Finnish LT population viral hepatitis and 
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alcoholic cirrhosis – both associated with renal dysfunction – are less frequent than at 
most centers. Furthermore, our patient population included proportionally more ALF 
patients (23%) than in most nations, where about 10% are acute patients. Finally, the 
present study included only first transplants; inclusion of retransplants would likely 
result in somewhat higher CKD incidence. 
ESRD, cumulatively affecting 2% of our patients by 5 years and 3% by 9 years, 
exhibited a slightly lower incidence rate than reported in other studies; Gonwa and 
colleagues140 reported a cumulative incidence of 3% by 5 years and Cohen and 
colleagues226 10% by 10 years. 
Cancer. The present study – estimating that one in six patients will develop some 
form of malignancy by 20 years after transplantation – confirms that for LT, cancer is 
a considerable long-term complication. The cumulative incidence rate of 13% at 10 
years and 16% at 20 years is, however, markedly lower than that reported by others 
(Table 5). Due to exceptionally precise cancer data in Finland, bias due to failure to 
notice some neoplasias does not explain this lower cancer rate. The difference might, 
however, be attributed to diverse patient population characteristics and to ethnic 
differences in various general populations. The infrequent utilization of antibody 
induction at our institution may also explain the lower cancer risk. Additional 
differences between studies are discussed in detail later. 
As in other reports (Table 5), nonmelanoma skin cancer and non-Hodgkin 
lymphoma predominated; accounting for 26% and 21% of all malignancies observed. 
Nonmelanoma skin cancer occurred mostly in older patients, and its risk did not vary 
between genders or by time after LT. This highlights the importance of regular skin 
exams at all posttransplant time-points, especially among the older recipients.  
Conversely, non-Hodgkin lymphoma more frequently affected males and 
patients transplanted at younger age, and more commonly developed early after LT. 
Cardiovascular risk factors. The present series leads to the estimate that among 
any 10 ALF patients having undergone LT, within 5 years, 1 has diabetes, 5 are 
overweight or obese, 6 have an abnormal lipid profile, and 7 are on antihypertensive 
medication. Whereas prevalence rates for hypertension and dyslipidemia are at the 
higher end of those reported in the literature, rates of obesity and diabetes are at the 
lower end.12,167,186,189-192 The incidence of new-onset diabetes, new-onset obesity, and 
new-onset need for of lipid-lowering medication, furthermore, emerged as somewhat 
more infrequent than in other reports.12,64,167,186,189-192 Whereas all the other series 
have examined CLD patients, the present study by intention included only ALF 
patients, because the health status of ALF patients shortly before transplantation is 
more closely comparable with that of the general population. Any deviation from 
population norms occurring after transplantation in the ALF group regarding the 
cardiovascular risk profile should thus be more attributable to transplant-related 
factors alone. 
CLD patients generally differ from our ALF patients in usually being older, in 
being more likely infected with HCV, and in displaying more co-mordibity and pre-





COMPARISON WITH THE GENERAL POPULATION 
Cancer. According to the present study, LT patients have a 2.6-fold higher cancer 
incidence than does the Finnish general population. Despite these cumulative 
incidence rates being markedly lower than in other studies, the SIR was similar to 
others’ (Table 6). Besides lymphoma and skin cancer, we did not observe other 
cancer types with significantly elevated SIRs, although some others have observed 
elevated SIRs for colorectal, pulmonary, and oropharyngeal cancers, as well as 
Kaposi sarcoma (Table 6).  
Table 18 assembles noteworthy differences between these studies that may 
explain some of the variation in their SIRs. Some series have not included children, 
whose relative cancer risk is the highest. The LT population of most institutions is, on 
average, also somewhat older than that in Finland. Elevated SIRs for colon cancer are 
mostly from locales where PSC is common, and increased SIRs for oropharyngeal 
neoplasias and lung cancer where alcoholic cirrhosis is common (Table 18).12,171 
HCV is, furthermore, linked to higher rates of PTLD,176 and in our population the 
number of patients with HCV is extremely low. Furthermore, lengths of follow-up 
differ, and relative cancer risk decreases along with longer follow-up times.  
Variation in risk for Kaposi sarcoma is likely explained by the strong regional 
variation in seroprevalence of human herpes virus 8: low in Finland and high, for 
instance, in Italy.168  
Risk for cancer relative to that of nontransplant controls of the same age and 
gender was higher for male LT patients than for their female counterparts. A likely 
reason is that PSC and alcoholic cirrhosis are more common among male patients. 
Cardiovascular risk. Among the ALF patients, hypertension exhibited a 2.7-fold 
higher prevalence than for the controls, whereas dyslipidemia and IFG were 
significantly less prevalent among the patients. Based on this, the pharmacotherapy 
used in LT patients clearly had caused hypertension, but it is possible that the often-
reported increased risk for diabetes in particular is related more to other factors.  
Our findings regarding diabetes and IFG imply that LT-related 
immunosuppressive treatment may elicit diabetes in susceptible patients – patients 
who in the absence of transplantation and immunosuppressive treatment might suffer 
only IFG. This finding therefore emphasizes the essence of assessing established risk 
factors for diabetes in clinical practice. It is also possible that transplant patients, as 
compared with controls, adopt a healthier life-style after LT, and this could explain, 
for instance, their lower prevalence of dyslipidemia and obesity. 
Only Sheiner and colleagues167 assessed CV risk factors by a similar SPR 
method, hence allowing a comparison of theirs with our data (Table 19). Increased 
risk for hypertension in their and our study is similar, possibly reflecting the use of 
cyclosporine as opposed to tacrolimus as the main CNI agent at both institutions 
(Table 19). The Sheiner group report also includes actual blood pressure 
measurements, and their inclusion likely elevates prevalence figures for hypertension 
relative to control figures. The reason may be that hypertension in the closely 
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Åberg et al 
2008 (Study 
II), Finland
Number of patients 121 174 1778 2034 417 779 540
Age at transplantation, 
years Median 48 Median 43 Median 50 N.A. Median 52 Mean 53 Mean 43
Follow-up, months Median 65   
(53-86)
Median 61     
(18-225)
Median 65   
(33-77)
N.A. Median 83 Median 49     
(0-288)















Proportion of children <5% 0% 0% >13% 0% 0% 14%
Proportion of alcoholic 
cirrhosis N.A. 6% 10% N.A. N.A. 24% 10%
Proportion of viral 
hepatitis 37% N.A. 21% N.A. N.A. 35% 3%
Proportion of PSC 9% 17% N.A. 
(autoimmune-
related, 46%)
10% N.A. <8% 14%
Overall SIR 3.9 4.3 2.1 2.5 2.6 1.9 2.6
Nonmelanoma skin 
cancer excluded from 
overall SIR Yes No No Yes Yes Yes No
SIR: Colon cancer N.S. Increased Increased Increased N.S. N.S. N.S.
SIR: Oropharyngeal 
cancer N.S. None observed N.S. N.S. Increased a Increased N.S.
SIR: Lung cancer N.S. N.S. Increased N.S. N.S. Increased N.S.
SIR: Kaposi sarcoma N.S. N.S. None 
observed
N.A. Increased N.S. N.A.
Table 18. Differences between cancer findings in studies reporting standardized incidence ratios (SIRs). 
Abbreviations: N.A., not available; N.S., not significant, PSC, primary sclerosing cholangitis




Sheiner and colleagues 167 noted a higher SPR for diabetes, despite their using a 
slightly higher glucose level in defining diabetes (Table 19). This difference may be 
attributed to their patients’ more frequent pre-existing diabetes, to their greater 
proportion of HCV infection, and to their more frequent long-term use of 
corticosteroids; such steroid use may in part also underlie their slightly higher SPR 
for both dyslipidemia and excessive weight. Interestingly, the rather high prevalence 
of pre-existing overweight/obesity among our ALF patients – as compared with their 
populations’ – decreased following LT, with posttransplant prevalence tending to be 
lower than expected. This contrasts with the weight gain typically seen among CLD 
patients after LT.167,194 
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Characteristics Sheiner et al,167 2000, USA Åberg et al 2009 (Study IV), Finland
Population assessed 5-year survivors Acute liver failure patients
Time-point of assessment ≥5 years (range 4.4-7.2) 5 years
Time-period of transplantation Prior to 1991 1987-2004
Number of patients 96 77
Age at transplantation, years Median 48 Mean 46
Characteristics of patients >90% chronic liver disease patients; All acute liver failure patients
33% hepatitis C virus
Main calcineurin inhibitor used Cyclosporine (80%) Cyclosporine (86%)
Proportion on long-term steroid therapy 
(dose)
98% (median prednisone 0.04 
mg/kg/day) 42% (mean methylprednisolone 2.9 mg)
Hypertension, SPR (95% CI) 3.1 (2.4-3.9) 2.7 (2.1-3.6)
Pre-existing, % 6% 12%
Definition BP >140/90 mmHg consecutively or 
>160/100 mmHg once
Antihypertensive medication
Diabetes, SPR (95% CI) 6.0 (4.2-8.4) 1.9 (0.8-3.7)
Pre-existing, % 18% 4%
Definition fP-glucose >7.8 mmol/L twice fP-glucose >7.0 mmol/L or antidiabetic 
medication
Overweight or obesity, SPR (95% CI) 1.2 (0.9-1.6) 0.75
Pre-existing, % 17% 58%
Definition Men: BMI ≥27.8 kg/m², Women: BMI 
≥27.3 kg/m²
BMI ≥25 kg/m²
Dyslipidemia, SPR (95% CI) 0.9 (0.6-1.4) 0.7 (0.5-0.9)
Pre-existing, % Not reported 4% (presence of medication)
Definition Serum cholesterol ≥6.22 mmol/L Fasting cholesterol ≥5.0 mmol/L, LDL 
≥3.0 mmol/L, HDL ≤1.0 mmol/L, 
triglycerides ≥2.0 mmol/L, or lipid-
lowering medication
Table 19. Comparison between present findings for cardiovascular risk factor prevalence and findings of 
Sheiner and colleagues.167
Cardiovascular risk factors
Abbreviations: BMI, body mass index; BP, blood pressure; fP-glucose, fasting plasma glucose; HDL, high-density lipoprotein; 











PRE- AND EARLY POSTTRANSPLANT RENAL FUNCTION TO DETERMINE 
COURSE OF LONG-TERM RENAL FUNCTION 
In LT recipients, a variety of potential factors may contribute to long-term renal 
dysfunction, factors tha may originate from the pre-, peri-, or posttransplant periods. 
In agreement with others’ findings,137,142,226,227 the most striking fall in renal function 
occurred between pretransplant and 1-year levels. This finding, together with the 
strong correlation between renal function at 1 year with function at up to 10 years, 
suggests that pre- and perioperative factors to a large extent determine long-term 
renal function. In particular, the better renal-function predictive value of GFR at 1 
year than pretransplant (a finding largely supported by others138,140,141,144,224,226,227) 
emphasizes the contribution of perioperative acute kidney injury to later renal 
dysfunction and to CKD. Several perioperative events, including clamping of the 
caval vein, hemodynamic instability, blood loss, infection, high-dose CNI, and other 
drug nephrotoxicity, may cause reversible or irreversible kidney damage. By the end 
of the first posttransplant year, the course for later renal function will have become 
apparent. For example, Ojo and colleagues139 noted a 2-fold higher CKD risk among 
patients who had experienced postoperative acute renal failure. 
Although less marked, a steady gradual decline in renal function continued 
during the following 10 years. Years 1 to 10 also demonstrated a gradual shift from 
stage 1 and 2 renal dysfunction to increased proportions of stage 3 and 4.  
In light of this, minimizing or avoiding long-term use of nephrotoxic drugs such 
as CNIs for patients with noticeable renal impairment at 1 year may prevent 
progression to CKD or ESRD. Less clear, however, is the need for such CNI-
avoidance in the subset of patients with well-preserved renal function at 1 year. This 
neglected issue deserves further investigation.  
Pretransplant renal impairment. Regarding pre-existing renal dysfunction, our 
findings suggest an indication-dependent pattern of reversibility in the sense that, 
following successful LT, even severe renal impairment in ALF patients often 
resolves, whereas moderate to severe impairment in CLD patients is most likely 
irreversible. With the same pattern, pretransplant GFR showed a moderate correlation 
with long-term renal function in the CLD group.  
This difference between CLD and ALF groups may be due to dissimilar 
etiologies underlying pretransplant renal dysfunction, or due to differences in the 
duration of such impairment. The etiology of pre-existing renal dysfunction was not 
investigated here, because few kidney biopsies were performed prior to LT. It can be 
speculated, however, that among CLD patients, such liver disease-independent 
kidney diseases as diabetic nephropathy or hypertensive kidney disease – both often 
irreversible – are more prevalent. Another explanation may be that a greater 
proportion of CLD patients are affected by type II hepatorenal syndrome, whereas 
type I is likely to predominate to complicate the course of ALF. The more slowly 
developing type II hepatorenal syndrome may prove less reversible – either through 
its longer duration or by its nature. We found that CLD patients required 3-fold 




CANCER AND CARDIOVASCULAR RISK IN RELATION TO 
IMMUNOSUPPRESSION REGIMEN AND REJECTION EPISODES 
Antibody induction therapy. Antibody therapy in the induction phase was associated 
with a 4-fold overall cancer risk, in particular, with a 6-fold risk for skin tumors. On 
the other hand, no increased cancer risk was evident when antibodies served as 
treatment for steroid-resistant rejection. During the period of our study, ATG (for 
induction) and OKT3 (for rejection) have been the main agents employed at our 
institution. Although it is well established that both of these preparations cause a risk 
for lymphoma,85,173 to our knowledge, no relationship has been reported with skin 
cancers. In addition, even if the development of nonmelanoma skin tumors strongly 
correlates with immunosuppression per se, the link is considered stronger for chronic 
maintenance immunosuppression than for short periods of intense 
immunosuppression, as with the use of antibodies.85,179 Any association between 
antibody induction therapy and skin cancer does therefore deserve future scrutiny. 
The nature of the association between antibody use and development of new-onset 
hypertension and diabetes also remains unclear.  
Maintenance immunosuppression. In addition to cyclosporine’s being the 
predominating CNI agent used at our institution, some patients have received both 
cyclosporine and tacrolimus sequentially, and in a retrospective study the reason for 
conversion is difficult to ascertain. For these reasons, a proper comparison between 
cyclosporine and tacrolimus is difficult to carry out. No obvious differences between 
these two were, however, observed. 
Although steroid withdrawal definitely conveys beneficial metabolic and CV 
effects,12,96 when comparing patients on steroids at 5 years to patients not using 
steroids at the same time point in Study IV, no such benefit was evident. This finding 
may, however, have at least two causes. First, all patients received steroids in the 
induction phase, and this may already elicit most of the CV derangements that, in 
general, steroids elicit. Second, the steroid doses received at the 5-year time-point 
were low: on average a daily 2.9 mg methylprednisolone. It is possible that such 
small steroid doses may cause no additional CV risk.   
Acute rejection. Interestingly, a history of acute rejection paralleled a 59% lower 
cancer incidence; one most strongly correlated with lymphomas. In this retrospective 
study setting, any explanation is difficult to provide. Patients who experience one or 
more rejection episodes may have been less immune suppressed, and, thus, at lower 
risk for cancer. The majority of rejection episodes, however, occur within 3 weeks, 
and differences in posttransplant immunosuppression levels during such a short 










QUALITY OF LIFE AND EMPLOYMENT OUTCOMES 
Although renal dysfunction, cancer, and various CV risk factors become increasingly 
prevalent after LT and often require medication, the HRQoL of patients remains 
comparable with that of the general population. Patients’ overall HRQoL differed in 
no clinically important ways from controls’ HRQoL. In some physical dimensions – 
including moving, sleeping, elimination, usual activities, and sexual activity –
however, LT patients displayed statistically significant deficits, but no corresponding 
level for a clinically important difference has been determined for the individual 
dimensions of the 15D instrument, as opposed to that for overall 15D score. LT 
patients, moreover, did not differ from controls in mental and psychological 
dimensions, and scored better on the dimension of discomfort and symptoms. 
A recent meta-analysis22 of 16 cross-sectional studies comparing HRQoL of LT 
patients with that of nontransplant control populations by means of the Short Form-36 
instrument likewise concluded that LT recipients displayed inferior ratings mainly in 
physical dimensions. The largest effect sizes were in physical functioning, role 
physical, energy, and general health,22 with pain and mental health demonstrating 
nonsignificant differences. These results would imply that novel posttransplant 
rehabilitation interventions should focus primarily on physical functioning. 
Longitudinal studies for the most part display an improvement in HRQoL pre- to 
posttransplant, but follow-up is usually limited to 1 or 2 years.22,108-111,113-116 We 
demonstrated in a cross-sectional fashion, with patients at different points of follow-
up, that although long-term survivors exhibited somewhat worse HRQoL than did 
medium-term survivors, this difference was due to their age. Increasing follow-up, 
conversely, seemed to produce no additional fall in HRQoL scores. 
Despite the improvement in HRQoL noted by others,22,108-111,113-116 and the 
improvement in working capacity reported by the majority (87%) of our recipients, 
only 43% of LT patients returned to work. Among those under 40 at LT, however, 
approximately 70 to 80% returned to work. In more than half of those unemployed 
after LT, early retirement was the explanation. As in other reports of quite similar 
overall posttransplant unemployment rates,22,117,119,122,123 we did not assess the 
medical conditions or complications underlying early retirement. Such assessment 
could facilitate prediction of posttransplant unemployment and enhance development 
of proper rehabilitation interventions. Nonetheless, considering the highly age-
dependent trend toward returning to work and the frequency of early retirement, our 
findings would support a strategy of performing LT at an earlier disease stage; 
specifically, before the disease has progressed so far that the patient is incapable of 
gainful employment and receives a disability pension. Early retirement before 
transplantation may restrain enthusiasm for returning to work, especially among older 
recipients, even if LT restores working capacity.  
 
FUTURE CONSIDERATIONS 
Until induction of allograft tolerance in LT eventually makes immunosuppression 
unnecessary, achieving adequate immunosuppression and simultaneously avoiding 
chronic drug toxicity remains a major challenge. Deciding on the best 
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immunosuppression regimen for the induction phase and then for early and long-term 
maintenance therapy requires characterization of the patient’s individual risk profile 
and tailoring of the immunosuppression regimen accordingly. The present work 
brings some new clarification to this subject, but at the same time raises some new 
questions. 
Risks and benefits of managing specific long-term complications by adjustments 
in immunosuppression therapy versus use of other means merit attention. Regarding 
traditional CV risk factors such as hypertension, thresholds for initiating 
pharmacotherapy and target levels for treatment await specific data for the LT 
population. Given the critical influence of CV disease on long-term outcome in this 
population, prospective studies would be appropriate. 
In the majority of cases, pre-existing renal impairment is, in CLD patients, 
unlikely to resolve. Studies investigating the etiology of such pre-existing dysfunction 
by kidney biopsy are, however, lacking. Awareness of the effects of etiology and 
duration of pretransplant renal dysfunction on its reversibility would, especially in 
CLD patients, aid in predicting post-LT renal function, and might assist in the 
difficult decision to proceed to combined liver-kidney transplantation. 
Especially in LT patients with marked renal impairment at 1 year, CNI-
minimization seems appropriate. On the other hand, the progression of mild to 
moderate renal dysfunction to CKD or ESRD is probably affected by factors other 
than CNI, but these remain uncharacterized. Chronic CNI nephrotoxicity in patients 
who have preserved renal function at 1 year but who are on long-term CNI also 
remains unclear. 
Regarding risk for malignancy, larger cohorts will better clarify which cancer 
types other than skin cancer and lymphoma may show an elevated incidence. Such 
studies should also further scrutinize the association shown here between acute 
rejection and cancer risk. 
Whether more intense cancer surveillance would have detected our patients’ 
malignancies at earlier stages remains unclear, as is whether survival would have 
been extended. Due to the small number of cancer cases in most such series, it is 
difficult to compare outcomes for specific neoplasias with outcomes in the 
nontransplant population. Limited data make it equally problematic to develop for the 
LT population any specific cancer-screening guidelines. With time, however, 
accumulating data from well-performed retrospective reports will elucidate these 
issues. 
One fundamental goal of LT is to restore the patient’s ability to return to work. A 
considerable proportion of patients, however, remained unemployed after LT. Current 
impressive outcomes in terms of survival and quality of life may justify transplanting 
patients at an earlier disease stage in order to support those remaining in the work 
force. Effective rehabilitation interventions encouraging a return to work should also 
be sought.  
With a longer perspective, identification of patients exhibiting allograft tolerance 
who may be completely weaned off immunosuppression, as well as the induction of 
such tolerance, emerge as important targets for the future. In an even longer view, 
hepatocyte transplantation or tissue engineering may provide an alternative to, or 
altogether replace, whole-liver transplantation. 
 74 
Conclusions 
Liver transplantation is a life-saving intervention that may change life expectancy for 
the majority of patients from a year or even a day to more than two decades. 
Although chronic complications are quite common and accumulate in the long term, 
the quality of life of liver transplant recipients, even over decades, nonetheless 
remains comparable with that of the general population.  
 
The following specific conclusions can be drawn:   
 
1. After liver transplantation, renal function generally deteriorates. The cumulative 
incidence of chronic kidney disease is 10% at 5 years and 16% at 10 years. Chronic 
renal impairment often has a multifactorial etiology, and the degree of irreversibility 
of pre- and perioperative kidney insults usually become evident by the end of the first 
posttransplant year, determining the course of later renal function. Pretransplant renal 
dysfunction is more often irreversible in patients with chronic liver disease than in 
patients with acute liver failure. 
 
2. Among patients transplanted for acute liver failure, 92% exhibited at least one 
cardiovascular risk factor at 5 years after transplantation: 71% received 
antihypertensive therapy, 61% had dyslipidemia, 10% had diabetes, 32% were 
overweight, and 13% obese. Compared with a matched Finnish general population, 
patients displayed a 2.7-fold hypertension prevalence, but significantly less frequently 
dyslipidemia or impaired fasting glucose. 
 
3. The cumulative incidence of malignancy increased from 5% at 5 years to 13% at 
10 years. Liver transplant patients were subject to a 2.6-fold cancer risk as compared 
with the general population’s. This elevated risk was mostly attributable to 
nonmelanoma skin cancer and lymphoma. Antibody induction therapy was associated 
with a 4.3-fold cancer risk (especially skin cancers), whereas acute rejection not 
requiring antibodies was associated with a lower cancer risk. 
 
4. Health-related quality of life was generally comparable among liver transplant 
patients and the Finnish general population. Patient quality of life scores decreased 
with age, but not with increasing time since transplantation. Although the majority of 
patients (87%) reported improved posttransplant working capacity, less than half 
(43%) of all patients had returned to working life – their most frequent reason being 
early retirement. Employment after transplantation exhibited an age-dependent trend, 
with the younger patients returning to work in 70% to 80% of cases. Being employed 
generally indicated better quality of life. 
 
Liver transplantation and associated immunosuppression therapy aggravated risk for 
renal dysfunction, cancer, and hypertension, and seemed linked with diabetes in 
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